A peer-reviewed Blood report found no statistically significant difference in recurrent stroke or all-cause mortality by initial hydroxyurea dose assignment over 4.9 years. The abstract gives no group counts or effect estimates, so it does not establish equivalent dosing.

GLOBAL / SUB-SAHARAN AFRICA / PAEDIATRIC STROKE PREVENTION / NOTABLE

Why it matters: Adds longer-term evidence for secondary stroke prevention in children with sickle cell anaemia in a resource-limited setting, while highlighting early risk after an initial stroke.

Evidence: Blood online-first article dated 26 October 2026 reports 4.9 years of pragmatic follow-up. Original SPRINT registry NCT02675790 first posted 5 February 2016, last updated 19 January 2022, completed 31 March 2020, with no registry results posted.; medium confidence.

Limitations: No statistically significant difference is not proof of equivalent dose strategies. The full paper could not be independently inspected at publication, so group counts, crossover, follow-up completeness and safety detail are not confirmed from the abstract. The original trial dates from 2016 to 2020; this is a new long-term report, not a new trial.

Sources

• Blood / American Society of Hematology: Initial fixed low-versus moderate-dose hydroxyurea assignment in the long-term follow-up of the SPRINT cohort
• ClinicalTrials.gov / Vanderbilt University Medical Center: SPRINT: NCT02675790

The US phase 1 registry now says withdrawn before enrolment, with zero actual participants and no treatment outcomes. This does not change access to established transplant programmes.

Previous: An archived registry mirror last updated 8 May 2026 listed the study as active and recruiting.

Current: ClinicalTrials.gov update posted 26 October 2026 lists withdrawn, actual enrolment zero, and closure to accrual because no participants accrued in the sponsor's system.

UNITED STATES / CITY OF HOPE / INVESTIGATIONAL TRANSPLANTATION / NOTABLE

Why it matters: The proposed US phase 1 pathway will not generate the anticipated human treatment evidence from this registered study.

Evidence: ClinicalTrials.gov NCT03279094 first posted 12 September 2017, last update posted 26 October 2026. An archived mirror last updated 8 May 2026 listed the prior status as active and recruiting. The current registry shows actual enrolment zero.; high confidence.

Limitations: The registry retains an estimated primary completion date of 25 January 2027 despite withdrawal; this is not an active milestone. No participants were treated, so no efficacy or safety inference is possible. This is one investigational protocol, not a withdrawal of haploidentical transplantation as a treatment category.

Sources

• ClinicalTrials.gov / City of Hope Medical Center: Haploidentical transplantation with pre-transplant immunosuppression: NCT03279094
• CenterWatch / ClinicalTrials.gov mirror: Earlier NCT03279094 recruiting snapshot

The peer-reviewed trial found a haemoglobin response in 56/138 people taking mitapivat versus 2/69 on placebo, but did not meet its pain-crisis co-primary endpoint. Mitapivat is not a UK sickle-cell treatment option.

GLOBAL / 69 SITES IN 15 COUNTRIES / ORAL DISEASE-MODIFYING THERAPY / MAJOR

Why it matters: The peer-reviewed controlled evidence strengthens the case that oral pyruvate-kinase activation can improve anaemia, while making clear it has not shown a statistically significant reduction in pain crises over the trial period.

Evidence: The Lancet Phase 3 report, publisher date 24 October 2026, available online by 23 October; 207 randomised participants followed for primary endpoints through weeks 24 to 52. Trial NCT05031780 first posted 2 September 2021, last updated 23 June 2026, active but not recruiting, with actual primary completion 30 October 2025 and estimated final completion February 2030, exact day not stated; high confidence.

Limitations: The study was funded by Agios Pharmaceuticals, and several authors had company ties. The trial did not establish fewer crises, prevention of organ damage, improved survival or durable benefit after treatment. A company topline announcement in November 2025 reported these primary outcomes earlier; this is the new peer-reviewed full report, not a new trial event.

Sources

• The Lancet / Elsevier: Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial
• ClinicalTrials.gov / Agios Pharmaceuticals: RISE UP: NCT05031780

One specialist NHS centre reports completion of the intensive treatment pathway. This is an implementation milestone and individual anecdote, not proof of a durable cure or a change in NICE eligibility.

UNITED KINGDOM / MANCHESTER PAEDIATRIC CENTRE / NHS GENE-THERAPY IMPLEMENTATION / NOTABLE

Why it matters: It is a concrete implementation milestone for England's managed-access pathway, showing treatment delivery through a specialist paediatric centre and regional and national sickle-cell panels.

Evidence: Manchester University NHS Foundation Trust report posted 23 October 2026; discharge dated 29 June 2026; current status reported by the hospital, with no specified observation period after infusion; high confidence.

Limitations: One person's short-term experience is anecdotal and cannot establish a durable cure or estimate efficacy or safety. Stem-cell collection, manufacturing, chemotherapy conditioning and a prolonged hospital stay were required. Infusion and bell-ringing dates, exact follow-up and wider centre totals were not stated.

Sources

• Manchester University NHS Foundation Trust: First UK sickle-cell Casgevy patient completes treatment
• NICE: TA1044: Exagamglogene autotemcel for treating severe sickle cell disease

The US phase 1 registry update posted 21 October lists a recruiting site for a five-person, ex-vivo CRISPR/Cas9 pilot. Participants require transfusions and myeloablative busulfan. No treatment results are posted.

Previous: An earlier public snapshot dated 28 September 2026 listed not yet recruiting. The registry first posted the study on 16 July 2026.

Current: Recruiting at Boston Children's Hospital; estimated enrolment five; estimated primary completion December 2028, exact day not stated.

UNITED STATES / BOSTON CHILDREN'S HOSPITAL / EX-VIVO GENE EDITING AND HbF REACTIVATION / NOTABLE

Why it matters: Recruitment has opened for another investigational HbF-reactivation approach, but no participant outcome has been posted and it does not change the clinical evidence for established or approved products.

Evidence: ClinicalTrials.gov NCT07708350, first posted 16 July 2026 and last update posted 21 October 2026; earlier 28 September public snapshot listed not yet recruiting; high confidence.

Limitations: Participants must meet severe-disease and transplant-fitness criteria, receive three months of transfusions and myeloablative busulfan, and agree to 15 years of follow-up. The intervention name describes bone-marrow-derived cells while the detailed protocol describes peripheral mobilisation and apheresis; collection method requires sponsor clarification. Estimated primary completion is December 2028, exact day not stated; final completion is estimated for December 2030. No efficacy or safety results are posted.

Sources

• ClinicalTrials.gov / Boston Children's Hospital: Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Sickle Cell Disease: NCT07708350
• Smart Patients / ClinicalTrials.gov mirror: Earlier NCT07708350 registry snapshot

The with-conditioning lane links the newly recruiting pilot. It directly tests ex-vivo BCL11A-enhancer editing after myeloablative busulfan; it does not advance evidence for a chemotherapy-free approach or report an outcome.

Previous: The conditioned HbF lane linked Casgevy, risto-cel and CS-206; it did not link the Boston BCL11A pilot.

Current: The lane also links the Boston pilot and explicitly notes its investigational status and lack of posted outcomes. The route's human-evidence stage and order are unchanged.

Sources

• ClinicalTrials.gov / Boston Children's Hospital: Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Sickle Cell Disease: NCT07708350
• NICE: TA1044: Exagamglogene autotemcel for treating severe sickle cell disease
• New England Journal of Medicine: Base Editing of HBG1 and HBG2 Promoters for Sickle Cell Disease
• Cell Stem Cell / Elsevier: Clinical base editing for beta-hemoglobinopathies across different genetic backgrounds

A secondary analysis of MRI scans from 929 children found an association with existing silent cerebral infarcts. It is an observational marker study, not a new screening rule or evidence that changing care improves outcomes.

UNITED STATES / SECONDARY TRIAL-IMAGING ANALYSIS / PAEDIATRIC STROKE AND DIAGNOSTICS / NOTABLE

Why it matters: The marker may help future work on identifying neurological risk in children with severe sickle-cell genotypes.

Evidence: British Journal of Haematology online first 19 October 2026; T2 MRI re-analysis of 929 of 1,191 participants in the earlier Silent Cerebral Infarct Transfusion Trial; medium confidence.

Limitations: Cross-sectional association in previously collected scans cannot show that the MRI feature predicts future infarcts or that acting on it prevents stroke. The study includes 929/1,191 participants and the abstract does not establish a clinically validated cut-off.

Sources

• British Journal of Haematology / Wiley: Association of enlarged perivascular space burden with silent cerebral infarcts in children with sickle cell disease

The Emory registry update posted 19 October records withdrawal because nobody enrolled. It does not answer whether prophylactic transfusion improves pregnancy outcomes.

Previous: Planned US Phase 4 randomised comparison with 50 estimated participants. The immediately preceding official status was not independently recovered.

Current: Withdrawn with zero actual participants and no results; the May 2028 estimated completion is obsolete.

UNITED STATES / EMORY UNIVERSITY, ATLANTA / PREGNANCY AND TRANSFUSION RESEARCH / NOTABLE

Why it matters: This removes one anticipated randomised evidence source on a consequential pregnancy-care question.

Evidence: ClinicalTrials.gov NCT06979492 first posted 20 May 2025; last update posted 19 October 2026; sponsor-reported withdrawal reason and zero actual enrollment; high confidence.

Limitations: The registry does not state the underlying decision date or why no one enrolled. Its estimated September 2026 start and May 2028 primary completion are obsolete; the immediately preceding official status was not independently recovered. Withdrawal is not evidence for or against prophylactic transfusion.

Sources

• ClinicalTrials.gov / Emory University: Prophylactic Transfusion In Pregnant in Women With Sickle Cell Disease: NCT06979492

A 64-centre expert process identified 24 essential and four recommended programme elements for gene-therapy delivery and long-term follow-up. This is US implementation consensus, not a new UK guideline or treatment result.

UNITED STATES / NATIONAL ALLIANCE OF SICKLE CELL CENTERS / GENE THERAPY IMPLEMENTATION AND FOLLOW-UP / NOTABLE

Why it matters: It makes the specialist capacity and follow-up needed for intensive gene-therapy pathways more explicit as access expands.

Evidence: Blood Advances online first 19 October 2026; modified Delphi process involving 64 US sickle-cell centres, with consensus predefined as at least 70% agreement; high confidence.

Limitations: Expert consensus from US centres, not comparative evidence that a specified delivery model improves safety or outcomes. It does not distinguish efficacy between CRISPR/Cas9 Casgevy, Cas12a reni-cel, base-edited risto-cel or other platforms, and it does not remove mobilisation or conditioning burden.

Sources

• Blood Advances / American Society of Hematology: National Alliance of Sickle Cell Disease Consensus Recommendations for Gene Therapy Implementation

A 20-person cardiac imaging sub-study reports improvements through up to 36 months after donor transplant and a non-randomised comparison at 12 months. It extends a 2024 report from the same programme, without proving fewer heart failures or resolving transplant safety concerns.

UNITED STATES / ST. JUDE CHILDREN'S RESEARCH HOSPITAL / TRANSPLANTATION AND CARDIAC COMPLICATIONS / NOTABLE

Why it matters: The longer follow-up strengthens evidence that successful transplantation can improve sickle-cell-related cardiac remodelling, a serious complication, rather than only control pain crises.

Evidence: British Journal of Haematology, online first 18 October 2026; serial cardiac imaging in 20 transplanted children and young adults, follow-up up to 36 months; age-matched non-randomised disease-modifying-therapy comparator at 12 months; medium confidence.

Limitations: Only 20 recipients were studied; the accessible abstract does not state the number evaluable at 36 months or the comparator size. The comparison was not randomised, and imaging surrogates do not establish reduced heart failure or mortality. NCT04362293 was last updated 1 September 2026, is active but not recruiting, had actual primary completion on 16 June 2026 and estimates final completion in August 2029. Its previous suspension cited serious adverse events, and this cardiac report does not resolve transplant safety. The matched-sibling and haploidentical regimens require a donor, thiotepa chemotherapy, low-dose total-body irradiation and immunosuppression, with post-transplant cyclophosphamide in the haploidentical arm.

Sources

• British Journal of Haematology / Wiley: Sustained improvement in sickle cell cardiomyopathy after haematopoietic stem cell transplantation is superior to that with disease-modifying therapy
• Blood / American Society of Hematology: Impact of hematopoietic cell transplantation on myocardial fibrosis in young patients with sickle cell disease
• ClinicalTrials.gov: Reduced-intensity transplantation for severe sickle cell disease: NCT04362293

The Maryland registry update posted 16 October lists recruitment open and increases estimated enrolment to 50 adults. This is a study-status change, not a pain-treatment result.

Previous: Not yet recruiting; 25 participants estimated in the previous registry version.

Current: Recruiting at one Maryland infusion centre; 50 participants estimated; no results posted.

UNITED STATES / MARYLAND / PAIN MANAGEMENT AND SUPPORTIVE-CARE RESEARCH / NOTABLE

Why it matters: A live randomised comparison can test feasibility, tolerability and preliminary analgesic effects during acute care, but opening recruitment does not demonstrate benefit.

Evidence: ClinicalTrials.gov NCT07674277; first posted 29 June 2026; last update posted 16 October 2026; one US site recruiting, 50 estimated adults; high confidence.

Limitations: This is a small, unmasked pilot with no posted results and a single US infusion-centre site. The registry lists recruiting despite a future estimated start date; recruitment may precede first enrolment. Primary completion is stated only as December 2027 and final completion only as March 2028, so no exact day is implied. Usual analgesia remains part of clinical care; the registry does not justify treatment changes.

Sources

• ClinicalTrials.gov / University of Maryland, Baltimore: Virtual Reality for SCD VOC, RELIEVE-SCD: NCT07674277

The 16 October registry update moved the estimated start and primary and final completion dates. The site now watches the 1 November 2026 estimated start while the study already lists recruiting status.

Previous: Estimated start 1 August 2026; primary completion August 2027; final completion December 2027.

Current: Estimated start 1 November 2026; primary completion December 2027; final completion March 2028. Exact completion days are not stated.

UNITED STATES / MARYLAND / PAIN MANAGEMENT AND SUPPORTIVE-CARE RESEARCH / NOTABLE

Why it matters: A live randomised comparison can test feasibility, tolerability and preliminary analgesic effects during acute care, but opening recruitment does not demonstrate benefit.

Evidence: ClinicalTrials.gov NCT07674277; first posted 29 June 2026; last update posted 16 October 2026; one US site recruiting, 50 estimated adults; high confidence.

Limitations: This is a small, unmasked pilot with no posted results and a single US infusion-centre site. The registry lists recruiting despite a future estimated start date; recruitment may precede first enrolment. Primary completion is stated only as December 2027 and final completion only as March 2028, so no exact day is implied. Usual analgesia remains part of clinical care; the registry does not justify treatment changes.

Sources

• ClinicalTrials.gov / University of Maryland, Baltimore: Virtual Reality for SCD VOC, RELIEVE-SCD: NCT07674277

A 19-patient retrospective study linked a proposed sickling pressure index with meeting pre-exchange HbS targets. The marker is not prospectively validated and does not yet justify changing an exchange schedule.

UNITED STATES / UNIVERSITY OF MIAMI / TRANSFUSION AND COMPLICATION MANAGEMENT / NOTABLE

Why it matters: Routine apheresis measurements might help identify patients who need individualised exchange scheduling if the index is validated prospectively.

Evidence: Transfusion, online first 16 October 2026; retrospective single-centre cohort of 19 patients and 115 chronic red-cell exchange procedures over 40 months; medium confidence.

Limitations: Only 19 patients from one centre were analysed, and 111 of 115 procedures contributed to the target-achievement comparison. The index was derived and assessed in the same cohort, with no external validation or patient-outcome test; no schedule or transfusion change follows from this result alone.

Sources

• Transfusion / AABB: The sickling pressure index predicts hemoglobin S target achievement during chronic red cell exchange in sickle cell disease

A US university team registered a planned 300-person randomized comparison of self-acupressure, sham acupressure and usual care for chronic sickle-cell pain. It is not yet recruiting, and the earlier small pilot cannot establish treatment benefit.

UNITED STATES / UNIVERSITY OF CINCINNATI AND UNIVERSITY OF CALIFORNIA, IRVINE / PAIN MANAGEMENT AND COMPLEMENTARY-THERAPY RESEARCH / NOTABLE

Why it matters: The sham arm and larger planned sample could test whether the symptom signal in a small 2025 exploratory study exceeds expectation and usual-care effects. Registration itself does not demonstrate benefit.

Evidence: ClinicalTrials.gov NCT07875777, first posted and last updated 15 October 2026; randomized, participant-masked, three-arm study with 300 estimated participants; no outcomes reported; high confidence.

Limitations: The study is not yet recruiting. Its 1 October 2027 start, 30 September 2032 primary completion and 31 March 2033 final completion are registry estimates, not confirmed results dates. Participants are asked to limit changes to pain medicines during study visits, but the record does not justify any treatment change outside the trial. The earlier 45-person feasibility study mixed randomized and non-randomized participants and had no sham comparison, so effectiveness and safety remain unproven.

Sources

• ClinicalTrials.gov / University of Cincinnati: Self-administered Acupressure in Patients With Sickle Cell Disease: NCT07875777
• Blood Advances / American Society of Hematology: Acupressure alleviates pain and clinical symptoms in patients with sickle cell disease

The newly posted ClinicalTrials.gov record estimates a 1 October 2027 start. This is a registry estimate, not confirmed recruitment or a results date.

Previous: No milestone for this newly registered study was displayed.

Current: Estimated study start on 1 October 2027 is displayed; the study is not yet recruiting.

UNITED STATES / UNIVERSITY OF CINCINNATI AND UNIVERSITY OF CALIFORNIA, IRVINE / PAIN MANAGEMENT AND COMPLEMENTARY-THERAPY RESEARCH / NOTABLE

Why it matters: The sham arm and larger planned sample could test whether the symptom signal in a small 2025 exploratory study exceeds expectation and usual-care effects. Registration itself does not demonstrate benefit.

Evidence: ClinicalTrials.gov NCT07875777, first posted and last updated 15 October 2026; randomized, participant-masked, three-arm study with 300 estimated participants; no outcomes reported; high confidence.

Limitations: The study is not yet recruiting. Its 1 October 2027 start, 30 September 2032 primary completion and 31 March 2033 final completion are registry estimates, not confirmed results dates. Participants are asked to limit changes to pain medicines during study visits, but the record does not justify any treatment change outside the trial. The earlier 45-person feasibility study mixed randomized and non-randomized participants and had no sham comparison, so effectiveness and safety remain unproven.

Sources

• ClinicalTrials.gov / University of Cincinnati: Self-administered Acupressure in Patients With Sickle Cell Disease: NCT07875777

A conference abstract first published on 6 October reports retinal findings from 618 adults at 18 NHS hospitals. It is newly verified for this tracker, not a 13 October study or UK screening-guideline change.

UNITED KINGDOM / 18 NHS HOSPITALS / EYE HEALTH AND SCREENING RESEARCH / NOTABLE

Why it matters: The findings support evaluating risk-adapted retinal screening in UK adult services, particularly because advanced disease may cause visual loss before symptoms are noticed.

Evidence: ASCAT 2026 abstract O72, first published online in British Journal of Haematology on 6 October; prospective cross-sectional study of 618 adults at 18 NHS hospitals; medium confidence.

Limitations: This is a conference abstract, not a full peer-reviewed report. Haematology-clinic recruitment does not produce a national prevalence estimate. Hydroxycarbamide use was associated with lower retinopathy stage, but the observational comparison cannot establish protection or justify a treatment change.

Sources

• British Journal of Haematology / ASCAT 2026: Burden of sight-threatening retinopathy and maculopathy in adults with sickle cell disease in the UK, abstract O72

The 6 October ASCAT abstract reports that 14 of 105 painful admission episodes at Royal Berkshire Hospital received analgesia within the existing 30-minute standard. This is a local service-quality finding, not a national rate.

UNITED KINGDOM / ROYAL BERKSHIRE HOSPITAL / ACUTE PAIN AND SERVICE QUALITY / NOTABLE

Why it matters: The audit identifies specific local opportunities to improve delivery of an existing acute-care standard.

Evidence: ASCAT 2026 abstract O06, first published online in British Journal of Haematology on 6 October; 105 admission episodes over four audit years; medium confidence.

Limitations: Single-centre retrospective episode audit reported only in a conference abstract. It does not evaluate a pathway intervention or establish a national trend. The 30-minute standard predates this report.

Sources

• British Journal of Haematology / ASCAT 2026: Real-world delays in analgesia for painful sickle crises: A 4-year single-centre audit, abstract O06

A 6 October industry-associated ASCAT abstract reports a transfusion signal in four evaluable simple-transfusion participants and a death after serious adverse events in a cohort of 13. Causality is not established; the study has no controlled SCD efficacy comparison.

GLOBAL MULTICENTRE / NO NEW UK ACCESS / TRANSFUSION AND INVESTIGATIONAL MEDICINES / NOTABLE

Why it matters: Offers an early, hypothesis-generating signal for a group with substantial transfusion burden, while making safety and attribution questions visible.

Evidence: ASCAT 2026 abstract O76, first published online in British Journal of Haematology on 6 October; GLADIOLUS phase 2 cohort of 13 chronically transfused participants with sickle cell disease; medium confidence.

Limitations: Only 13 people enrolled, with four evaluable in the simple-transfusion response denominator; no randomised comparator, individualised transfusion schedules, and no demonstrated stroke-prevention outcome. The registry is completed, last updated 16 December 2025, and has no posted results. Its actual primary completion was 3 September 2025.

Sources

• British Journal of Haematology / ASCAT 2026: Transfusion-dependent SCD: Management challenges and emerging phase 2 evidence for etavopivat, abstract O76
• ClinicalTrials.gov: GLADIOLUS etavopivat study: NCT04987489

A peer-reviewed synthesis of 18 studies from nine high-prevalence countries links sustainable prenatal and newborn screening to government support, integration with care, community knowledge and stigma reduction. It did not test a new programme or measure a mortality benefit.

NINE HIGH-PREVALENCE COUNTRIES IN AFRICA / GLOBAL EVIDENCE SYNTHESIS / SCREENING, PREVENTION AND HEALTH-SYSTEM ACCESS / NOTABLE

Why it matters: Brings together implementation evidence for early diagnosis in high-prevalence settings, where a positive test only helps when children can access continuing care.

Evidence: BMC Global and Public Health, online first 8 October 2026; 18 qualitative papers from Angola, Cameroon, DR Congo, Ghana, Liberia, Nigeria, Senegal, Tanzania and Uganda; GRADE-CERQual used to assess themes; medium confidence.

Limitations: The search covered 30 eligible countries but included studies from only nine, with Ghana and Tanzania overrepresented; three papers addressed prenatal screening alone. Qualitative themes do not quantify screening uptake, mortality benefit or programme cost, and some review findings had low confidence.

Sources

• BMC Global and Public Health / Springer Nature: A qualitative evidence synthesis on perinatal screening for sickle cell disease in high-burden countries

A peer-reviewed analysis followed 606 children across four African countries and recorded 5,493 infections over 5,638 person-years. Infection incidence was not higher during hydroxyurea treatment, including at maximum tolerated dose. The open-label phase comparison cannot prove the medicine caused lower infection rates.

ANGOLA, DR CONGO, KENYA AND UGANDA / FOUR HOSPITALS / PAEDIATRIC TREATMENT SAFETY AND GLOBAL ACCESS / MAJOR

Why it matters: Adds substantial long-term, four-country safety evidence addressing a barrier to hydroxyurea use in lower-resource paediatric care.

Evidence: The Lancet Haematology, online first 7 October 2026; REACH phase 1/2 treatment trial, 606 treated children aged 1 to 10; 5,493 clinically diagnosed infections over 5,638 person-years; high confidence.

Limitations: This was a retrospective within-cohort comparison of treatment phases, not a randomised treated-versus-untreated infection study. Clinically diagnosed infections may be misclassified, and age, follow-up care or time trends may contribute to lower rates. It does not establish the best dose for an individual child. The main REACH registry was last updated 30 June 2026 and is active, not recruiting; its actual primary completion was 1 July 2018 and final completion is estimated for August 2033. The extension registry was last updated 21 April 2026, is active, not recruiting, and estimates primary completion on 4 October 2027.

Sources

• The Lancet Haematology / PubMed: Incidence of clinically diagnosed infections in children with sickle cell anaemia treated with oral hydroxyurea in Angola, DR Congo, Kenya, and Uganda
• ClinicalTrials.gov: Realizing Effectiveness Across Continents With Hydroxyurea: NCT01966731
• ClinicalTrials.gov: Realizing Effectiveness Across Continents With Hydroxyurea: NCT06171217

In a two-centre retrospective study of 145 pregnancies, new red-cell antibodies were recorded in 1 of 26 people given chronic transfusion and 5 of 119 given on-demand transfusion. The small number of events cannot establish equal safety or change pregnancy guidance.

TWO CENTRES / EXACT LOCATIONS NOT STATED IN ABSTRACT / PREGNANCY AND TRANSFUSION / NOTABLE

Why it matters: Adds data to a difficult pregnancy transfusion decision and suggests a gap between guideline criteria and practice in the studied cohort.

Evidence: Transfusion, online first 7 October 2026; two-centre analysis of 145 pregnancies, 26 managed with chronic transfusion and 119 with on-demand transfusion; medium confidence.

Limitations: Only six new alloimmunisation events make the comparison underpowered; no significant difference is not proof of equivalent risk. Retrospective treatment selection, incomplete data and variable antigen matching limit causal interpretation. The paper did not test maternal or infant outcome benefits from chronic transfusion.

Sources

• Transfusion / PubMed: No difference in alloimmunization of pregnant adults with sickle cell disease exposed to chronic versus on-demand transfusions

A retrospective study found that 97 of 262 chronic-disease paediatric admissions at one private Luanda hospital involved sickle cell anaemia. Longer intensive-care stays and more transfusions show a local service burden, not a national Angolan rate or a tested intervention.

ANGOLA / ONE PRIVATE TERTIARY HOSPITAL / PAEDIATRIC SERVICE BURDEN AND EQUITY / NOTABLE

Why it matters: Quantifies the local inpatient and resource burden of sickle cell anaemia in an underrepresented setting, supporting scrutiny of access to earlier and continuing care.

Evidence: BMC Pediatrics, online first 7 October 2026; retrospective comparison of 262 chronic-disease paediatric admissions within 1,169 total admissions in 2024; medium confidence.

Limitations: Retrospective data from a relatively well-resourced private tertiary hospital with a predominantly insured population cannot represent all Angolan children. Admission selection and underlying disease differences limit comparisons. No care intervention or national outcome change was tested.

Sources

• BMC Pediatrics / Springer Nature: Burden of sickle cell anemia among hospitalized children in Angola: a retrospective study

A peer-reviewed US observational claims analysis reports an association between prior voxelotor prescribing and fewer red-cell transfusions. It does not establish a causal benefit or reverse the 2024 withdrawal after safety concerns about crises and deaths. Voxelotor is not available as a current treatment.

UNITED STATES / HISTORICAL CLAIMS DATA / TRANSFUSION AND DRUG SAFETY CONTEXT / NOTABLE

Why it matters: Adds a historical observational signal about transfusion burden while illustrating why a favourable individual outcome cannot establish overall clinical benefit or restore a withdrawn medicine.

Evidence: Accepted peer-reviewed manuscript, online first 6 October 2026; propensity-score-matched US claims analysis, 164 voxelotor-exposed people and 289 comparators; several authors affiliated with Pfizer; medium confidence.

Limitations: Non-randomised claims data can retain confounding and prescribing bias despite matching. Transfusion count is not a comprehensive safety or clinical-outcome measure. The study does not show that voxelotor is safe or that withdrawal should be reversed. This is an accepted manuscript that may receive copy edits.

Sources

• Journal of Sickle Cell Disease / Oxford University Press: Real-world effectiveness of voxelotor in individuals with sickle cell disease and history of red blood cell transfusions
• MHRA / GOV.UK: Class 2 medicines recall: Oxbryta 500 mg tablets

The observational late-effects study now has a November 2026 estimated primary completion on the site's milestone watch list. This is an existing registry estimate newly tracked here, not a newly announced date or results date.

Previous: November 2026 COALESCE primary-completion estimate was not displayed in the site's milestone list.

Current: November 2026 registry-estimated primary completion is displayed; exact day not stated.

UNITED STATES / FIVE CENTRES / LONG-TERM OUTCOMES AFTER CURATIVE THERAPIES / NOTABLE

Why it matters: The smaller, now-closed cohort sets the scale of forthcoming late-effects evidence, relevant to weighing benefits and risks of intensive curative approaches.

Evidence: ClinicalTrials.gov observational cohort NCT05153967, first posted 10 December 2021 and updated 6 October 2026; independent change history confirms the previous registry values; high confidence.

Limitations: No outcome results or safety signal are posted. The registry does not explain why actual enrollment is below the earlier estimate or give an exact recruitment-closure date. Primary completion is estimated for November 2026 and final completion for February 2027, with no exact day stated.

Sources

• ClinicalTrials.gov: Cooperative Assessment of Late Effects for SCD Curative Therapies: NCT05153967

An update posted on 6 October changed the US observational study from recruiting to active, not recruiting, and replaced an estimated enrollment of 750 with 377 actual participants. No safety or effectiveness findings have been posted.

Previous: Recruiting; 750 participants estimated.

Current: Active, not recruiting; 377 participants actual. Estimated primary completion November 2026 and final completion February 2027.

UNITED STATES / FIVE CENTRES / LONG-TERM OUTCOMES AFTER CURATIVE THERAPIES / NOTABLE

Why it matters: The smaller, now-closed cohort sets the scale of forthcoming late-effects evidence, relevant to weighing benefits and risks of intensive curative approaches.

Evidence: ClinicalTrials.gov observational cohort NCT05153967, first posted 10 December 2021 and updated 6 October 2026; independent change history confirms the previous registry values; high confidence.

Limitations: No outcome results or safety signal are posted. The registry does not explain why actual enrollment is below the earlier estimate or give an exact recruitment-closure date. Primary completion is estimated for November 2026 and final completion for February 2027, with no exact day stated.

Sources

• ClinicalTrials.gov: Cooperative Assessment of Late Effects for SCD Curative Therapies: NCT05153967
• ClinicalTrials.gg, independent ClinicalTrials.gov change tracker: COALESCE study registry change history

A registry update posted on 5 October lists one Abidjan site as recruiting for a 120-infant study of point-of-care sickle-cell screening linked to early care. A second site has not opened recruitment. The study has no outcome results and estimated primary completion is December 2029.

CÔTE D'IVOIRE / ABIDJAN / NEWBORN SCREENING AND EARLY CARE / NOTABLE

Why it matters: Tests whether linking a rapid newborn result to an early-care pathway can improve outcomes in a low-resource setting, beyond simply detecting the condition.

Evidence: ClinicalTrials.gov Phase 4 single-group health-services registry; NCT07488520; update submitted 30 September and posted 5 October 2026; recruiting status at one site; estimated 120 infants; high confidence.

Limitations: Recruitment and actual start dates do not establish effectiveness. This is a small non-randomised study using historical comparison; no outcome results are posted. Primary completion is registry-estimated for December 2029. The registry does not show an exact date on which recruitment began.

Sources

• ClinicalTrials.gov: Integrating Point of Care Testing for Newborn Screening and Early Care for Sickle Cell Disease in Yopougon: NCT07488520

Kenya's Defence Forces Memorial Hospital reports a red-cell exchange performed on 2 October using a newly acquired apheresis system. This adds a specialist capability for eligible hospital beneficiaries, not a national service rollout or evidence of improved long-term outcomes.

KENYA / DEFENCE FORCES MEMORIAL HOSPITAL / TRANSFUSION AND SERVICE ACCESS / NOTABLE

Why it matters: Adds a specialist transfusion capability at one Kenyan hospital that may reduce the need for outside referral for eligible patients.

Evidence: Kenya Ministry of Defence account of the hospital's first red-cell exchange with its new apheresis equipment; medium confidence.

Limitations: One procedure and a government announcement do not establish sustained capacity, patient outcomes or availability beyond eligible Defence Forces hospital beneficiaries. This is not a national rollout.

Sources

• Kenya Ministry of Defence: DFMH advances specialised blood care with first red blood cell exchange

A peer-reviewed Canada and France study of 440 adults found that RUDAS may help identify some people for fuller neurocognitive assessment. At the reported threshold, sensitivity was only 50%, so a normal score cannot rule out impairment. No UK pathway change or improved patient outcome was shown.

CANADA AND FRANCE / THREE CENTRES / COGNITIVE ASSESSMENT AND DIAGNOSTICS / NOTABLE

Why it matters: The findings give services a more specific basis for considering a brief route to fuller cognitive evaluation, while showing why this score should not be treated as a rule-out test.

Evidence: Peer-reviewed multicentre assessment of the Rowland Universal Dementia Assessment Scale in 440 adults; a prespecified subset received a multidisciplinary reference assessment; medium confidence.

Limitations: Participants came from three specialist centres in Canada and France, and diagnostic performance was assessed against a reference diagnosis in a prespecified subset rather than all 440 adults. Low sensitivity means many people with impairment could be missed. No trial tested whether screening improves patient outcomes.

Sources

• Blood Advances / PubMed: Brief Cognitive Assessment in Sickle Cell Care: Psychometric Properties of the RUDAS Across Two Languages

A peer-reviewed observational analysis found that 42.4% of 205 insured young people met its definition of successful transfer to adult care. It highlights a service gap, but does not test a fix or establish UK rates.

UNITED STATES / ALABAMA, COLORADO AND INDIANA / CARE CONTINUITY AND DISPARITIES / NOTABLE

Why it matters: The study puts a measurable number on an important care-continuity gap and supports closer scrutiny of specialist access during transition to adult services.

Evidence: Peer-reviewed observational analysis of CDC Sickle Cell Data Collection records from three US states; 205 insured young people aged 15 to 20; medium confidence.

Limitations: Only three US states and continuously insured young people were included. The two-visit definition does not capture care quality, and the study cannot show that transfer status caused differences in emergency use. No intervention or patient-outcome improvement was tested.

Sources

• Journal of Adolescent Health / PubMed: Multistate Analysis of Transfer to Adult Care in Sickle Cell Disease

Roche announced a CE-marked multiplex dried-blood-spot screening kit with an optional HBB component. This is a company-reported product launch, not evidence of better detection or outcomes in practice, and no NHS adoption has been confirmed.

CE-MARK-ACCEPTING MARKETS / UK USE UNCONFIRMED / NEWBORN SCREENING AND DIAGNOSTICS / NOTABLE

Why it matters: A combined assay could give laboratories another screening option, but this announcement does not show that programmes have adopted it or that it improves diagnostic accuracy or patient outcomes.

Evidence: Roche company announcement and manufacturer product information, not an independent screening-performance or implementation study; medium confidence.

Limitations: The claims come from the manufacturer. The product page does not state its publication date, so the exact first availability date is not established. No independent validation, real-world uptake or outcome results were identified. Screening findings require confirmatory follow-up.

Sources

• Roche / TIB MOLBIOL via PR Newswire: Roche launches newborn screening test for three severe genetic conditions
• Roche Diagnostics: LightMix Kit TREC SMA HBB Newborn CE-IVD product information

A new, explicitly speculative research map compares HBB correction to HbA, HbS conversion to HbG-Makassar, and fetal-haemoglobin reactivation. Each route has a without-conditioning hypothesis and a with-conditioning comparator, linked to original evidence and the existing ledger. The ordering is a monitoring priority, not a clinical ranking or claim that a chemotherapy-free cure exists.

Previous: No structured research-route map on SCD Watch.

Current: Three mechanisms, six evidence-labelled research lanes, with an assumption and next evidence gate for each route.

Sources

• Tessera Therapeutics: New preclinical data advancing an in vivo sickle-cell programme
• Molecular Therapy / PubMed: Development of CRISPR_SCD001 after CRISPR-Cas9 correction of the sickle mutation
• Nature: Base editing of haematopoietic stem cells rescues sickle cell disease in mice
• Science / PubMed Central: In vivo hematopoietic stem cell modification by mRNA delivery
• Nature Biomedical Engineering / PubMed: In vivo genome editing of human haematopoietic stem cells for treatment of blood disorders using mRNA delivery
• NICE: TA1044: Exagamglogene autotemcel for treating severe sickle cell disease
• New England Journal of Medicine: Base Editing of HBG1 and HBG2 Promoters for Sickle Cell Disease
• Cell Stem Cell / Elsevier: Clinical base editing for beta-hemoglobinopathies across different genetic backgrounds

The full 7 September Cell Stem Cell article identifies busulfan-based myeloablative conditioning. The earlier tracker wording relied on the accessible abstract and registry, which did not state the regimen. CS-206 is not chemotherapy-free; the original paper date has not changed.

Previous: Conditioning regimen not stated in the accessible abstract or trial registry.

Current: Publisher full text describes busulfan-based myeloablative conditioning.

CHINA / NIGERIA / GLOBAL / GENE AND CELL THERAPY / MAJOR

Why it matters: This is the first peer-reviewed clinical case reported for this transformer base-editing platform in sickle cell disease. It shows that the approach can edit and return a person's own blood stem cells and produce a strong fetal-haemoglobin response. It does not establish effectiveness across patients or justify calling the treatment a cure.

Evidence: Peer-reviewed descriptive report from three early trials; one participant had sickle cell disease; high confidence.

Limitations: Only one person with sickle cell disease was reported, with no comparator and 15.5 months of follow-up. The industry-sponsored Early Phase 1 trial is still recruiting, estimates five participants and has no registry results posted. The publisher's article describes busulfan-based myeloablative conditioning alongside cell collection, laboratory editing and reinfusion, so this is not chemotherapy-free. No off-target mutations were detected, but testing cannot prove that none occurred. Several authors are founders, advisers or employees of CorrectSequence Therapeutics.

Sources

• Cell Stem Cell / PubMed: Clinical base editing for beta-hemoglobinopathies across different genetic backgrounds
• Cell Stem Cell / Elsevier: Clinical base editing for beta-hemoglobinopathies across different genetic backgrounds

The EMA first published this draft on 24 September, before the previous site update. It proposes how confirmatory phase 3 sickle-cell medicine trials should assess efficacy and safety, including diverse genotypes and longer-term risks. Consultation runs until 31 January 2027. It is not final guidance and does not change treatment access today.

EUROPEAN UNION / GLOBAL TRIAL RELEVANCE / REGULATORY AND TRIAL DESIGN / NOTABLE

Why it matters: The proposal could shape how future sickle-cell trials are designed and what evidence supports European benefit-risk decisions. The original publication was 24 September; this tracker record is a later backfill, not a new 29 September regulatory action.

Evidence: EMA draft regulatory guideline, not final guidance or evidence of treatment efficacy; high confidence.

Limitations: It is only a draft under consultation. Its final wording, adoption date and effect on individual development programmes are not yet known. It does not provide new patient outcome data.

Sources

• European Medicines Agency: Draft guideline on the clinical requirements for medicines intended for the treatment of sickle cell disease

UCLH says its Red Cell Network is funding Clinical Nurse Specialist roles at Norfolk and Norwich University Hospital and Lister Hospital. The roles are already operating. The announcement does not give start dates, staffing levels, funding amounts or patient outcomes, and is not a national staffing change.

ENGLAND / TWO LOCAL HOSPITALS / SPECIALIST SERVICE AND WORKFORCE / NOTABLE

Why it matters: This is a concrete example of specialist haemoglobinopathy support being funded at two local hospitals. It may help patients access expertise closer to home, but the size and measured effect of the change are not yet clear.

Evidence: UCLH Red Cell Network service report, not a national staffing audit or patient-outcomes study; high confidence.

Limitations: UCLH does not give role start dates, the number or full-time equivalent of posts, funding amount or duration, how many patients benefit, or measured clinical outcomes. Its statement about addressing needs is not independently quantified.

Sources

• UCLH / The Red Cell Network: Raising awareness of sickle cell disorder

An updated overview finds moderate-certainty evidence that long-term transfusion lowers stroke risk in children and adolescents at high risk. It also highlights weak evidence for many other uses, sparse adult trials and iron-overload risk. This consolidates existing trial evidence, not a new treatment approval.

GLOBAL / UK CLINICAL RELEVANCE / TRANSFUSION AND STROKE PREVENTION / MAJOR

Why it matters: This makes clear which transfusion benefit is well supported and where evidence remains thin. It synthesises existing trials, rather than reporting a new trial or changing a treatment licence.

Evidence: Updated Cochrane overview of 17 reviews; five reviews with usable transfusion comparisons included nine randomised trials and 1,502 participants; high confidence.

Limitations: Most other outcomes had very-low-certainty evidence and adult trials were sparse. The review notes iron-overload risk, and treatment decisions depend on the individual clinical situation. The published abstract does not establish a universal transfusion strategy.

Sources

• Cochrane Database of Systematic Reviews / PubMed: Red blood cell transfusion to treat or prevent complications in sickle cell disease: an overview of Cochrane reviews

Researchers used shielded viral vectors and chemoselection in humanized mice to deliver a fetal-globin-inducing construct to stem cells. This is preclinical viral gene transfer, not CRISPR editing, and there are no treated patients or human safety results.

INTERNATIONAL / PRECLINICAL / GENE AND CELL THERAPY / NOTABLE

Why it matters: Delivering treatment directly to stem cells inside the body could eventually reduce the need for laboratory editing of collected cells. This approach uses viral gene transfer and gene silencing, not the CRISPR-Cas9 DNA cut used by Casgevy.

Evidence: Peer-reviewed Cell Stem Cell study in mobilized humanized mice, not a human clinical trial; medium confidence.

Limitations: No people were treated. The mice were mobilized and chemoselection was required; the study does not establish that a future human treatment would avoid conditioning, be safe, prevent crises or work durably.

Sources

• Cell Stem Cell / PubMed: Systemic delivery of phagocytosis-shielded retroviral vectors enables in vivo HSC gene therapy for sickle cell disease

A model trained in 598 adults and tested in a separate 383-person cohort predicted five-year mortality better than comparators. It is not a deployed clinical tool and no prospective study shows that using it improves care or survival.

UNITED STATES / GLOBAL RESEARCH RELEVANCE / RISK PREDICTION AND SERVICE INNOVATION / NOTABLE

Why it matters: More accurate risk estimates could help identify people who may need closer follow-up or consideration of intensive treatment, if future prospective testing demonstrates useful and fair decisions.

Evidence: Observational model development in 598 adults and external validation in a separate cohort of 383 adults; medium confidence.

Limitations: External validation is still observational. The abstract does not report calibration or subgroup fairness results, and no study shows that model-guided care improves survival. A risk prediction is not a prognosis for an individual person.

Sources

• Blood Advances / PubMed: Advancing mortality risk prediction in sickle cell disease through multi-task deep learning models

A UN-hosted event formally launched a partnership intended to coordinate sickle-cell financing, comprehensive care and accountability across countries. This is a policy and implementation signal, not a new treatment, funding award or measured improvement in access.

GLOBAL, WITH HIGH-BURDEN COUNTRY PRIORITY / GLOBAL HEALTH POLICY AND ACCESS / NOTABLE

Why it matters: A standing coordination mechanism could help move existing guidance and proven interventions into high-burden health systems. Its impact will depend on published commitments, funding, country plans and measured delivery.

Evidence: United Nations-hosted launch event and recording; policy and implementation signal, not clinical evidence; high confidence.

Limitations: This is a launch, not proof of delivery. The available UN record does not quantify new financing, specify binding country commitments or provide patient-outcome data.

Sources

• United Nations Web TV / World Health Organization: OneSCD: A Global Partnership to Advance Equity and Transform Sickle Cell Care

A rule-based method classified disease and trait from clinical reports with 94.0% positive predictive value in a manually reviewed sample, compared with 58.1% to 88.3% for ICD-10-code-only approaches. It may improve research datasets but is not a diagnostic test for patients.

FRANCE / GLOBAL RESEARCH METHODS / DIAGNOSTICS AND RESEARCH DATA / NOTABLE

Why it matters: Research based only on administrative codes can mix disease subtypes or include people with trait, distorting prevalence and outcome estimates. This validation offers a reproducible way to improve retrospective datasets.

Evidence: Peer-reviewed validation of a rule-based clinical-text algorithm against manual review of 1,510 patients in five French specialist centres; medium confidence.

Limitations: Performance may depend on the specialist centres' documentation and patient mix. A positive predictive value is not overall diagnostic accuracy, and this is a research-record classification method, not a patient-facing diagnostic test.

Sources

• Journal of Medical Systems / Springer Nature: Classifying Sickle Cell Disease Subtypes from Clinical Reports: Algorithm Validation and ICD-10 Accuracy Assessment in Five French Hospitals

In a 91-person US survey, most adults with sickle cell disease were comfortable discussing genetic transmission, but 65% of partnered participants said their partner did not know their sickle-cell-trait status. The single-centre, unvalidated survey cannot establish wider prevalence or the effectiveness of counselling.

UNITED STATES / GLOBAL / REPRODUCTIVE HEALTH AND GENETIC COUNSELLING / NOTABLE

Why it matters: The findings identify a gap between willingness to discuss genetic risk and partners knowing their trait status. They support research into more consistent, practical reproductive and genetic counselling for women and men with sickle cell disease.

Evidence: Peer-reviewed secondary analysis of survey responses from 91 adults with sickle cell disease aged 21 to 39 at one US medical centre; medium confidence.

Limitations: The sample was small and came from one centre. The survey was not validated, qualitative responses came from one open-ended question, and self-reporting may introduce recall or interpretation bias. The study does not show that genetic counselling changes decisions or outcomes.

Sources

• Journal of Assisted Reproduction and Genetics / PubMed: Identifying potential factors influencing family-building perspectives in adults with SCD

A 14-study review projects a substantial global burden, particularly in Africa, and calls for screening, specialist evaluation and neurosurgical capacity. The authors label the estimates exploratory because evidence from high-burden regions is sparse.

GLOBAL, WITH AFRICA PRIORITY / STROKE, MOYAMOYA AND GLOBAL WORKFORCE / NOTABLE

Why it matters: The review highlights a mismatch between the likely neurological burden in high-prevalence regions and access to transcranial Doppler screening, imaging, specialist medical management and paediatric neurovascular surgery. It frames workforce and diagnostic capacity as part of stroke prevention.

Evidence: Peer-reviewed PRISMA systematic review of 14 studies, combined with 2021 global disease estimates; medium confidence.

Limitations: The global numbers are modelled, not counted cases. Evidence from Africa and other high-burden regions was extremely limited, and surgical series may over-represent severe referred cases. There is no standard universal indication for revascularisation, so the projected surgical number must be treated as exploratory rather than a treatment target.

Sources

• Child's Nervous System / PubMed: Global burden of moyamoya syndrome in pediatric sickle cell disease and implications for the neurosurgical workforce

Among 18,213 children admitted with acute pancreatitis, the 286 with sickle cell disease had longer stays and more transfusions, endoscopic procedures and cholecystectomies. The retrospective database comparison does not establish causation or a preferred treatment strategy.

UNITED STATES / GLOBAL / PAEDIATRICS AND GASTROINTESTINAL COMPLICATIONS / NOTABLE

Why it matters: The study quantifies the additional hospital and procedural burden when acute pancreatitis occurs in children with sickle cell disease. It may help define questions for earlier gallstone detection, coordinated haematology and gastroenterology care, and future comparative research.

Evidence: Peer-reviewed retrospective Pediatric Health Information System analysis of 18,213 children admitted with acute pancreatitis, including 286 with sickle cell disease; medium confidence.

Limitations: This retrospective US hospital-database comparison cannot show that sickle cell disease itself caused the differences or that more procedures improved outcomes. Coding, case mix, pancreatitis cause, sickle genotype and disease severity may affect the results. It provides no treatment-effect estimate.

Sources

• Journal of Pediatric Gastroenterology and Nutrition / PubMed: Children with sickle cell disease hospitalized for acute pancreatitis have an increased disease burden

Late-added peer-reviewed evidence, originally published on 20 September, found diagnosed depression rose from 20.3% in 2016 to a 25.7% peak in 2020 and remained above 25% in 2022. Claims data cannot measure undiagnosed symptoms or show causation.

UNITED STATES / GLOBAL / MENTAL HEALTH AND CARE DISPARITIES / NOTABLE

Why it matters: The study adds longitudinal evidence that mental-health burden remained high even after the wider Medicaid rate fell from its 2020 peak. It supports closer attention to depression identification and care alongside physical sickle-cell management, especially for younger adults and women.

Evidence: Peer-reviewed retrospective analysis of Texas Medicaid administrative claims from January 2016 to July 2023; medium confidence.

Limitations: The analysis covers one US state's Medicaid population and identifies diagnosed depression from claims rather than measuring symptoms. Undiagnosed depression, coding differences, race, care access and other confounding factors may affect the comparison. It cannot show that sickle cell disease caused depression.

Sources

• British Journal of Haematology / PubMed: Temporal trends and demographic patterns in depression prevalence among adults with sickle cell disease

The original study was published on 14 September, not 21 September. Across 2,698,556 Quebec pregnancies, sickle cell crises were associated with substantially higher maternal morbidity and adverse birth outcomes. The observational design does not prove that crises caused each outcome.

CANADA / GLOBAL / PREGNANCY AND MATERNAL SAFETY / NOTABLE

Why it matters: The study distinguishes the added risk associated with a recorded sickle cell crisis from sickle cell anaemia without a crisis in a very large population dataset. It reinforces the need for specialist pregnancy planning, rapid assessment and continued monitoring after an acute episode.

Evidence: Peer-reviewed population-based retrospective cohort covering 2,698,556 Quebec pregnancies from 1989 to 2022; medium confidence.

Limitations: This is an observational analysis of administrative data from Quebec. Coding, changes in care over 33 years, residual confounding and small numbers within some sickle-cell subgroups may affect the estimates. Relative risks do not establish that a crisis directly caused each outcome.

Sources

• British Journal of Haematology / PubMed: Sickle cell anaemia with and without crises: An observational study of pregnancy outcomes

A manufacturing and preclinical paper reports direct correction of the sickle mutation with CRISPR-Cas9. A nine-person US Phase 1/2 trial is recruiting, but the paper contains no human outcomes and reports more disrupted than corrected HBB alleles.

UNITED STATES / GLOBAL / GENE EDITING, PRECLINICAL AND EARLY TRIAL / NOTABLE

Why it matters: Unlike Casgevy, which disrupts a BCL11A control region to reactivate fetal haemoglobin, this approach attempts to repair the sickle mutation itself. The publication provides a reproducible manufacturing and preclinical evidence package for an approach now entering human testing.

Evidence: Peer-reviewed manufacturing and preclinical study linked to a recruiting nine-person, single-group Phase 1/2 US trial; high confidence.

Limitations: The paper reports no outcomes in people. More HBB alleles were disrupted than corrected, so the clinical balance of corrected, disrupted and unedited cells is unresolved. The trial is open-label, single-group, estimates only nine participants and has no posted results.

Sources

• Molecular Therapy / PubMed: Development of CRISPR_SCD001 after CRISPR-Cas9 correction of the sickle mutation
• ClinicalTrials.gov: CRISPR_SCD001 Phase 1/2 trial: NCT04774536

The new 400-person Phase 4 PAMAVOC trial will compare morphine and paracetamol with combinations adding ketamine, nefopam, tramadol or ketoprofen. It has not started recruiting and has no results.

FRANCE / GLOBAL / PAIN AND VASO-OCCLUSIVE CRISIS / NOTABLE

Why it matters: A shared adaptive platform could compare several commonly considered adjunct pain treatments within one protocol. Its size and randomisation may produce more useful comparative evidence than a series of small separate studies.

Evidence: New 400-person randomised open-label adaptive platform-trial registry record, with no results; high confidence.

Limitations: The trial is not yet recruiting, has no listed locations and no results. It is open-label, and the estimated primary completion is 14 October 2029. Registry entry is not evidence that any tested combination is safer or more effective.

Sources

• ClinicalTrials.gov: PAMAVOC adaptive pain-management platform trial: NCT07826988

In 129 adults, the highest allostatic-load group had higher odds of pain crises and emergency-department use. The observational design shows association, not that stress caused the outcomes or that the measure is ready for routine clinical use.

UNITED STATES / GLOBAL / PAIN, STRESS AND SOCIAL DETERMINANTS / NOTABLE

Why it matters: The study connects clinical burden with a measurable combination of biological stress and social conditions. It may help shape further research into risk and interventions that address both disease biology and social determinants.

Evidence: Peer-reviewed cross-sectional analysis of 27 biomarkers in 129 adults with sickle cell disease; medium confidence.

Limitations: Association does not show that cumulative stress caused pain crises or emergency use. The sample was small, the biomarker index needs external validation, and social conditions, disease severity and care access may influence one another. The measure is not ready for individual clinical prediction.

Sources

• Blood Advances / PubMed: Cumulative stress measured by allostatic load and vaso-occlusive episodes

A peer-reviewed mouse study reports improvements in blood measures and reduced spleen enlargement after inducing haptoglobin expression. It is preclinical and does not show safety or benefit in people.

BRAZIL / GLOBAL / GENE THERAPY, PRECLINICAL / NOTABLE

Why it matters: The work explores a different therapeutic target: limiting damage linked to free haemoglobin released during chronic haemolysis rather than editing the sickle mutation or increasing fetal haemoglobin.

Evidence: Peer-reviewed sickle-cell mouse study using gene therapy to induce haptoglobin expression; medium confidence.

Limitations: Results in mice do not establish safety, dosing or benefit in people. The study did not show that haptoglobin prevented haemolysis in humans, and no clinical-development timetable is reported.

Sources

• PLOS One / PubMed: Therapeutic potential of haptoglobin in a murine model of sickle cell anaemia

A bioRxiv preprint reports laboratory sickle-cell mutation correction and beta-thalassaemia results in humanised mice using EPOR-linked expansion. It is not peer reviewed and provides no human sickle-cell outcome or clinical availability.

UNITED STATES / GLOBAL / GENE EDITING, PRECLINICAL / NOTABLE

Why it matters: The approach tackles a major in vivo gene-editing problem: too few corrected blood stem cells may persist to produce a useful proportion of healthy red cells. If replicated and shown safe, preferential expansion could help, but this is only an early research strategy.

Evidence: Unreviewed preprint: laboratory experiments in an erythroid cell line and primary human CD34+ cells, plus humanised mice engrafted with beta-thalassaemia patient cells; low confidence.

Limitations: Not peer reviewed. The mouse disease model was beta-thalassaemia, not sickle cell disease; sickle mutation correction was a laboratory component, not an in vivo SCD efficacy demonstration. No people were treated. Long-term EPOR-editing safety, off-target effects, vector immune response and suitability of the mobilization regimen for sickle cell disease remain unknown. No claim of being chemotherapy-free in patients is supported.

Sources

• bioRxiv: In vivo HSPC gene therapy of hemoglobinopathies without drug selection of corrected cells

The HIBISCUS 2 Phase 3 registry now says 2 to 15 prior crises rather than 1 to 15 and increases estimated enrolment from 408 to 510. A 2025 sponsor poster already said 2 to 15, so whether the real entry rule changed is unconfirmed. No results are posted.

UNITED KINGDOM / MULTINATIONAL / TRIAL RECRUITMENT AND ELIGIBILITY / NOTABLE

Why it matters: Prospective participants need accurate public eligibility information. The larger target changes the planned scale of this placebo-controlled efficacy study, but does not mean etavopivat has been shown to work.

Evidence: ClinicalTrials.gov Phase 3 randomised trial record, consecutive registry versions 19 and 20; high confidence.

Limitations: A sponsor poster from 2025 already specified 2 to 15 crises, so the registry text change may correct an inconsistency rather than tighten the actual protocol. This is not a trial result or clinical recommendation. Estimated enrolment is not actual enrolment, recruitment can vary by site, and completion dates are estimates.

Sources

• ClinicalTrials.gov: HIBISCUS 2 etavopivat Phase 3 trial, NCT06612268: registry amendment
• Novo Nordisk / ASH 2025: HIBISCUS 2 trial-in-progress poster

A retrospective US study of 37 deliveries reports postpartum transfusions and readmissions, with breastfeeding persistence falling over six months. It supports continued postpartum follow-up but cannot establish causes or change UK guidance.

UNITED STATES / GLOBAL / PREGNANCY AND POSTPARTUM CARE / NOTABLE

Why it matters: The paper adds dated, specific evidence that sickle-cell care needs to continue beyond delivery, including attention to haematological complications and feeding support. It does not show that a particular transfusion strategy or breastfeeding intervention improves outcomes.

Evidence: Peer-reviewed retrospective single-centre cohort of 37 deliveries from 2015 to 2025; medium confidence.

Limitations: Only 37 deliveries at one centre were studied retrospectively. Subgroup comparisons were exploratory, numbers differ slightly across outcomes because of missing data, and selection and confounding prevent causal conclusions. Do not interpret falling breastfeeding persistence as caused by sickle cell disease alone.

Sources

• Journal of Perinatal Medicine / PubMed: Postpartum outcomes in sickle cell disease: transfusion exposure, maternal morbidity, and breastfeeding persistence

The trial registry first posted final results on 16 September. Of 46 treated participants, 42 (91.3%) met the 12-month severe-crisis-free endpoint. Safety results include 22 people with serious adverse events and one death, previously assessed by FDA as unlikely to be related to the edited cells themselves.

MULTINATIONAL / GLOBAL, INCLUDING THE UK / GENE THERAPY AND TRIAL RESULTS / MAJOR

Why it matters: This is the first public results posting in the trial registry for the pivotal sickle-cell study, adding a full treated-population denominator and detailed safety outcomes to earlier publications and company summaries. The results reinforce a substantial reduction in severe crises for many treated people, while showing that not everyone met the endpoint and that treatment is intensive.

Evidence: Sponsor-reported final results in ClinicalTrials.gov from the single-arm Phase 2/3 CLIMB-121 study, with an earlier FDA clinical assessment of the reported death; high confidence.

Limitations: There was no randomised comparator. The endpoint is 12 consecutive months without a severe crisis, not proof of lifelong cure, and long-term durability and late risks still need follow-up. Busulfan myeloablative conditioning carries major risks. The registry lists one death in its 12-month transplant-related mortality outcome; the earlier FDA review attributed this multifactorial respiratory death to COVID-19 and possible busulfan injury and judged it unlikely to be related to the edited cells themselves. Do not infer product causality from the registry table alone. The registry results are sponsor reported and have not independently established a new regulatory or NHS decision.

Sources

• ClinicalTrials.gov: CLIMB-121 Casgevy sickle-cell trial, NCT03745287: posted results
• US Food and Drug Administration: December 2023 clinical review memo for Casgevy

The watch card was revised because final CLIMB-121 results are now public, while EMA adoption and any UK access change remain unconfirmed.

Previous: EMA submission confirmed; final CLIMB-121 results not yet public in the cited agenda.

Current: Final CLIMB-121 registry results posted; EMA assessment and UK managed-access position unchanged.

MULTINATIONAL / GLOBAL, INCLUDING THE UK / GENE THERAPY AND TRIAL RESULTS / MAJOR

Why it matters: This is the first public results posting in the trial registry for the pivotal sickle-cell study, adding a full treated-population denominator and detailed safety outcomes to earlier publications and company summaries. The results reinforce a substantial reduction in severe crises for many treated people, while showing that not everyone met the endpoint and that treatment is intensive.

Evidence: Sponsor-reported final results in ClinicalTrials.gov from the single-arm Phase 2/3 CLIMB-121 study, with an earlier FDA clinical assessment of the reported death; high confidence.

Limitations: There was no randomised comparator. The endpoint is 12 consecutive months without a severe crisis, not proof of lifelong cure, and long-term durability and late risks still need follow-up. Busulfan myeloablative conditioning carries major risks. The registry lists one death in its 12-month transplant-related mortality outcome; the earlier FDA review attributed this multifactorial respiratory death to COVID-19 and possible busulfan injury and judged it unlikely to be related to the edited cells themselves. Do not infer product causality from the registry table alone. The registry results are sponsor reported and have not independently established a new regulatory or NHS decision.

Sources

• ClinicalTrials.gov: CLIMB-121 Casgevy sickle-cell trial, NCT03745287: posted results
• European Medicines Agency: PRAC agenda, 31 August to 3 September 2026: Casgevy procedure EMA/VR/0000356719
• NICE: TA1044: Exagamglogene autotemcel for treating severe sickle cell disease

A peer-reviewed study in humanized HbSS mice found that iron chelation reduced kidney iron and protected kidney function in male mice. The result was not reproduced in female mice and is not evidence that chelation prevents kidney disease in people.

UNITED STATES / GLOBAL / KIDNEY COMPLICATIONS AND PRECLINICAL RESEARCH / NOTABLE

Why it matters: The study supports renal iron as one possible contributor to sickle-cell kidney damage and highlights a biological difference between male and female mice. It gives researchers a mechanism to investigate further, but it does not show that adding or changing iron-chelation treatment prevents kidney disease in people with sickle cell disease.

Evidence: Peer-reviewed preclinical study in humanized HbSS mice; high confidence.

Limitations: This was a mouse study, not a human trial. The apparent protective effect was sex-specific and the mechanism was not fully explained. Animal results often do not translate into clinical benefit, and the study provides no evidence for changing a person's treatment, medicine or dose.

Sources

• American Journal of Physiology - Renal Physiology / PubMed: Impact of renal iron overload on sickle cell nephropathy in a humanized mouse model

ClinicalTrials.gov now records the multicentre paediatric study as completed with 190 participants and an actual completion date of 31 October 2022. No results have been posted, so the update does not show whether ultrasound detected acute chest syndrome accurately.

Previous: Recruiting, with estimated enrolment of 150 and estimated completion dates in 2023.

Current: Completed, with actual enrolment of 190 and actual primary and final completion on 31 October 2022; no results posted.

FRANCE / GLOBAL / ACUTE CHEST SYNDROME AND DIAGNOSTICS / NOTABLE

Why it matters: The completed cohort is larger than originally estimated and could help assess whether bedside ultrasound detects lung changes linked to acute chest syndrome earlier or with less radiation than repeated chest X-rays. The registry update only confirms that data collection ended. It does not report diagnostic accuracy or clinical outcomes.

Evidence: ClinicalTrials.gov prospective multicentre diagnostic-study registry update; high confidence.

Limitations: The registry was updated nearly four years after the recorded completion date and gives no explanation for the delay. No results are posted and no peer-reviewed findings were identified, so sensitivity, specificity, safety and clinical usefulness cannot be judged. Registry completion is not evidence that the test works.

Sources

• ClinicalTrials.gov: Pulmonary ultrasound for acute chest syndrome in children with sickle cell disease: NCT03971136

A 98-patient retrospective study found different presentations in children with HbSC and HbSS or sickle beta-zero thalassaemia. Hydroxyurea use was associated with higher haemoglobin and fewer transfusions in the HbSS or sickle beta-zero group, but the design cannot prove a treatment effect.

GERMANY / AUSTRIA / GLOBAL / INFECTION AND PAEDIATRIC COMPLICATIONS / NOTABLE

Why it matters: Parvovirus B19 is best known for causing a sudden fall in red-cell production. This study suggests its presentation may differ by sickle-cell genotype and adds real-world evidence about how children already taking hydroxyurea fared during infection. It may help frame further clinical research, but it does not create a new treatment or care recommendation.

Evidence: Peer-reviewed retrospective multicentre observational study; high confidence.

Limitations: The analysis was retrospective and treatment was not randomised. Children receiving hydroxyurea may have differed from untreated children in ways the study could not fully control, so the associations do not prove that hydroxyurea caused fewer transfusions. The abstract does not report adjusted effect sizes for every comparison or establish a genotype-specific management pathway.

Sources

• British Journal of Haematology / PubMed: Parvovirus B19 infections in children with sickle cell disease

Fourteen strokes occurred across 2,173 patient-years in 195 people with HbSS or sickle beta-zero thalassaemia. The cohort had no overt stroke before age 10 and an increasing incidence with age, but the small event count and population-specific factors limit wider conclusions.

SAUDI ARABIA / GLOBAL / STROKE AND NEUROLOGICAL COMPLICATIONS / NOTABLE

Why it matters: The age pattern differs from the recognised childhood stroke peak in many HbSS populations. The authors suggest higher fetal haemoglobin, wider hydroxyurea use and supportive care may contribute, while leaving room for population-specific factors. The study helps describe long-term cerebrovascular risk in an underrepresented population rather than proving why the pattern differs.

Evidence: Peer-reviewed longitudinal observational cohort study; high confidence.

Limitations: Only 14 strokes occurred, which limits precision and multivariable analysis. This was an observational cohort concentrated in southwestern Saudi Arabia, treatment changed over time and residual confounding is likely. The apparent absence of an early childhood peak may not generalise to other genotypes, ancestries or health systems.

Sources

• British Journal of Haematology / PubMed: Stroke incidence and phenotype in Saudi patients with sickle cell disease

Qualitative interviews in England found that migrant parents coordinated care across health, education and welfare systems while repeatedly self-advocating within fragmented services. The study argues for condition-specific navigation support but does not test a service intervention.

ENGLAND / CARE ACCESS AND FAMILY EXPERIENCE / NOTABLE

Why it matters: The study makes visible the practical and emotional work families do when services do not join up around them. Its main implication is a service-design question: whether condition-specific navigation support should be built into specialist care rather than leaving families to connect systems themselves.

Evidence: Peer-reviewed qualitative interview study; high confidence.

Limitations: Qualitative interviews explain experiences but cannot estimate how common they are across all migrant families or all UK services. The abstract does not state the participant count, and the study did not test whether a navigation service improves access or health outcomes.

Sources

• Sociology of Health & Illness / PubMed: Migrant parents and the everyday labour of managing sickle cell disease in the UK

The recruiting observational study moved its estimated primary and final completion from 31 May 2028 to 31 May 2030. The registry gives no reason for the delay and posts no results.

Previous: Primary and final completion estimated for 31 May 2028.

Current: Primary and final completion estimated for 31 May 2030; status remains recruiting.

UNITED STATES / GLOBAL / DIAGNOSTICS AND BIOMARKERS / NOTABLE

Why it matters: The two-year move means evidence from this long-running diagnostic-technology study is now expected later. Recording it prevents the previous 2028 estimate from being treated as current or as a likely results date.

Evidence: ClinicalTrials.gov observational-study milestone change; high confidence.

Limitations: This is an estimated timeline change, not a result. The registry gives no reason for the extension, posts no results and does not provide a confirmed publication date. The study is observational and has a single listed site.

Sources

• ClinicalTrials.gov: Sickle cell disease biofluid chip technology: NCT02824471

The updated PRAC agenda confirms that Vertex submitted final CTX001-121 sickle-cell results and interim CTX001-131 long-term follow-up results. The procedure was listed for adoption, but the agenda does not publish the results or prove that final product information has taken effect.

Previous: The 31 August submission deadline had passed, but public confirmation of receipt had not been identified.

Current: Submission is confirmed in EMA procedure EMA/VR/0000356719, listed for PRAC adoption at the 31 August to 3 September meeting.

EU / GLOBAL / REGULATION / MAJOR

Why it matters: This closes the earlier uncertainty about whether the required evidence was submitted. It moves the evidence from a due-date watch into formal regulatory consideration, but it does not reveal the detailed results or create a new treatment decision by itself.

Evidence: Regulatory obligation; high confidence.

Limitations: The agenda confirms submission and that adoption was the planned committee action. It does not publish participant-level findings, show whether the committee adopted the update, or confirm when revised product information will take effect. The meeting minutes are not yet publicly available.

Sources

• European Medicines Agency: Casgevy product information and specific obligations
• European Medicines Agency: PRAC agenda, 31 August to 3 September 2026: Casgevy procedure EMA/VR/0000356719

The watch card no longer says receipt is unconfirmed. It now separates confirmed submission and regulatory consideration from the still-unpublished study results and any final product-information outcome.

Previous: Final pivotal and long-term data were due, with public confirmation of receipt still being checked.

Current: EMA confirms the data were submitted and entered procedure EMA/VR/0000356719; detailed results and a final adopted product-information outcome are still awaited.

EU / GLOBAL / REGULATION / MAJOR

Why it matters: This closes the earlier uncertainty about whether the required evidence was submitted. It moves the evidence from a due-date watch into formal regulatory consideration, but it does not reveal the detailed results or create a new treatment decision by itself.

Evidence: Regulatory obligation; high confidence.

Limitations: The agenda confirms submission and that adoption was the planned committee action. It does not publish participant-level findings, show whether the committee adopted the update, or confirm when revised product information will take effect. The meeting minutes are not yet publicly available.

Sources

• European Medicines Agency: PRAC agenda, 31 August to 3 September 2026: Casgevy procedure EMA/VR/0000356719

The latest HIBISCUS 3 registry version changes four Indian sites from recruiting to completed. The 27-person Phase 2 study remains recruiting overall at sites in Nigeria and Oman, with another Indian site not yet recruiting.

Previous: Four Indian sites were recruiting; one Indian site was not yet recruiting; sites in Nigeria and Oman were recruiting.

Current: Four Indian sites are completed; one Indian site is not yet recruiting; sites in Nigeria and Oman remain recruiting.

INDIA / NIGERIA / OMAN / GLOBAL / STROKE PREVENTION AND DRUG DEVELOPMENT / NOTABLE

Why it matters: The change suggests enrolment or study activity has finished at most listed Indian centres while recruitment continues elsewhere. It is progress in a study testing whether etavopivat changes a blood-flow measure used to identify stroke risk, but it is not evidence that the medicine prevents stroke.

Evidence: ClinicalTrials.gov Phase 2 trial registry status change; high confidence.

Limitations: This is a site-status change, not a result. The non-randomised open-label study is small, its primary outcome is change in transcranial Doppler velocity at week 12, and estimated primary and final completion remain 20 August 2027 and 28 June 2028. Completed site status does not show how many participants finished or whether the study met its outcome.

Sources

• ClinicalTrials.gov: Etavopivat in children at increased risk of stroke: NCT05953584

The randomised 60-person paediatric study remains not yet recruiting and moved its estimated start from August to November 2026. Its estimated December 2027 primary completion did not change.

Previous: Estimated study start August 2026.

Current: Estimated study start November 2026; status remains not yet recruiting.

UNITED STATES / GLOBAL / NEUROCOGNITIVE COMPLICATIONS / NOTABLE

Why it matters: The delay moves the earliest likely recruitment window by about three months. The study is an exploratory test of whether delivering near-infrared light through the scalp is feasible and safe enough to study for cognitive and brain-oxygenation outcomes in children with sickle cell disease.

Evidence: ClinicalTrials.gov randomised feasibility-trial milestone change; high confidence.

Limitations: No participant results are available and the trial is not yet recruiting. It is primarily designed around feasibility and acceptability, not definitive clinical benefit. Primary completion remains estimated for December 2027 and final completion for December 2029.

Sources

• ClinicalTrials.gov: Transcranial photobiomodulation in children with sickle cell disease: NCT06797583

The Atlanta study now records an actual 1 September start and remains recruiting. It plans to compare four weeks of daily virtual music therapy with standard educational material in 25 young people.

Previous: Study start estimated for 1 September 2026.

Current: Study start recorded as actual on 1 September 2026; recruitment remains open.

UNITED STATES / GLOBAL / PAIN AND SUPPORTIVE CARE / NOTABLE

Why it matters: The update confirms that a small controlled study of a low-burden supportive intervention has started. Randomisation is useful, but the sample is intended to explore signals and mechanisms rather than provide a definitive answer about pain care.

Evidence: ClinicalTrials.gov randomised supportive-care trial launch; high confidence.

Limitations: This is a trial-start confirmation, not a result. The estimated sample is only 25, participants know which group they are in, outcomes include self-reported measures and final completion is estimated for 1 April 2028.

Sources

• ClinicalTrials.gov: Music therapy for pain and psychosocial outcomes in young people with sickle cell disease: NCT07562451

A retrospective study of 270 adults found circulating nucleated red blood cells in 65.6% and linked their presence with lower haemoglobin and laboratory signs of altered red-cell production. Prospective validation is still needed before the count can guide care.

FRANCE / GLOBAL / BIOMARKERS AND DISEASE MECHANISMS / NOTABLE

Why it matters: The count is already obtainable from blood analysis and could become a practical marker for separating biologically different patient groups. The study identifies an association and a research direction, not a test that can yet predict complications or choose treatment.

Evidence: Peer-reviewed retrospective observational biomarker study; high confidence.

Limitations: The study was retrospective and cannot establish causation. Hydroxyurea use differed between groups, the reported acute-chest-syndrome association was only a trend, and no prospective threshold or clinical decision rule was validated. The PubMed abstract does not provide enough information to assess all residual confounding or disclosure details.

Sources

• American Journal of Hematology / PubMed: Circulating nucleated red blood cells in adults with sickle cell disease

The HMA-EMA study catalogue now records an actual 1 September start for the required survey of healthcare professionals, earlier than the planned 30 September date. It tests understanding and use of Casgevy safety materials, not patient outcomes.

Previous: Survey start planned for 30 September 2026.

Current: Survey started on 1 September 2026; final report remains planned for 31 December 2027.

EUROPEAN UNION / GLOBAL / GENE THERAPY SAFETY MONITORING / NOTABLE

Why it matters: This is part of the regulatory system for checking whether risk-minimisation information is reaching clinicians in practice. It monitors knowledge and use of safety materials, not whether Casgevy is effective or whether new adverse events have occurred.

Evidence: HMA-EMA required post-authorisation study record; high confidence.

Limitations: The study is a web survey of healthcare professionals rather than patient follow-up. Starting it does not indicate a new safety signal. Data analysis is planned from 1 January 2027, an interim report for 30 April 2027 and a final report for 31 December 2027.

Sources

• HMA-EMA: Casgevy healthcare-professional risk-minimisation survey

A two-clinic retrospective study of 328 people with HbSS found higher haemoglobin and fewer infections associated with hydroxyurea use. The adjusted vaso-occlusive-crisis estimate was uncertain, and the study cannot establish causation.

KENYA / GLOBAL / HYDROXYUREA AND ACCESS / NOTABLE

Why it matters: The study adds implementation evidence from a setting that is underrepresented in sickle-cell research. It supports the importance of access and adherence around an established medicine, while showing how difficult it is to separate treatment effects from real-world differences between patients.

Evidence: Peer-reviewed two-clinic retrospective observational study; high confidence.

Limitations: Treatment was not randomised, the data are from 2019 to 2021 and unmeasured differences may explain some associations. The adjusted vaso-occlusive-crisis estimate was 0.82 with a 95% confidence interval of 0.66 to 1.02, while the major-complication estimate was imprecise. The design cannot establish that lower doses work as well as higher doses or that hydroxyurea caused the observed differences.

Sources

• Frontiers in Medicine / PubMed: Hydroxyurea treatment in Nairobi informal settlements

The estimated 10 September start has passed, but the registry has not been updated since 2 September. It still labels the study recruiting while keeping the start date estimated, so the milestone is removed from the upcoming list and remains under verification.

Previous: Estimated start 10 September 2026, with recruiting status already shown.

Current: Start date has passed without confirmation; latest registry update remains 2 September 2026.

UNITED STATES / GLOBAL / PAIN MANAGEMENT / NOTABLE

Why it matters: The triple-masked design could produce more useful evidence about whether low-dose ketamine reduces opioid need during acute vaso-occlusive pain than uncontrolled treatment reports.

Evidence: ClinicalTrials.gov registry milestone change; high confidence.

Limitations: The registry still labels the study recruiting even though its revised start date is in the future. That inconsistency needs confirmation, and the update is a schedule change rather than a clinical result.

Sources

• ClinicalTrials.gov: Low-dose ketamine for acute sickle-cell pain: NCT07369024

The England service card now records that patients are receiving genomically matched blood and that rollout covers around 17,000 people with sickle cell disorder. It also keeps the evidence limit visible: national outcome reductions have not yet been reported.

Previous: Specialist pathway matters: NHS England commissions coordinating centres, specialist teams and a national haemoglobinopathy panel.

Current: Genomic blood matching has moved into national use, with rollout to around 17,000 people with sickle cell disorder and outcome data still awaited.

ENGLAND / TRANSFUSION AND SERVICE DELIVERY / MAJOR

Why it matters: The programme has moved beyond collecting and testing samples into using genomic results to select blood for transfusion. A fuller blood-group profile can reveal variants that conventional testing may miss and can support closer matching for people who need repeated transfusions.

Evidence: NHS national service implementation report; high confidence.

Limitations: This is an implementation report, not a comparative outcomes study. More precise matching is intended to reduce antibody formation and transfusion reactions, but the announcement does not provide national data showing how much either outcome has changed. The dates of the first genomically matched transfusions are not stated.

Sources

• University College London Hospitals NHS Foundation Trust: First patients benefit from genomically matched blood transfusions through national programme
• NHS England: Blood-group genotyping test launched for inherited blood disorders

UCLH reports that patients across England are now receiving more precisely matched transfusions using genomic blood-group information. The programme is rolling out nationally to around 17,000 people with sickle cell disorder.

Previous: NHS blood-group genotyping was offered nationally, with future use of the results for more precise matching planned.

Current: Genomically informed blood matching is now being used for patient transfusions in England.

ENGLAND / TRANSFUSION AND SERVICE DELIVERY / MAJOR

Why it matters: The programme has moved beyond collecting and testing samples into using genomic results to select blood for transfusion. A fuller blood-group profile can reveal variants that conventional testing may miss and can support closer matching for people who need repeated transfusions.

Evidence: NHS national service implementation report; high confidence.

Limitations: This is an implementation report, not a comparative outcomes study. More precise matching is intended to reduce antibody formation and transfusion reactions, but the announcement does not provide national data showing how much either outcome has changed. The dates of the first genomically matched transfusions are not stated.

Sources

• University College London Hospitals NHS Foundation Trust: First patients benefit from genomically matched blood transfusions through national programme
• NHS England: Blood-group genotyping test launched for inherited blood disorders

The registry now lists all 12 trial locations in France and Guadeloupe as recruiting, up from one of 11 locations in the preceding posted version. The 104-person trial tests whether intravenous lidocaine reduces opioid use during severe vaso-occlusive crisis.

Previous: One of 11 locations was recruiting in the version posted 13 July 2026.

Current: All 12 listed locations are recruiting in the version posted 9 September 2026.

FRANCE / GUADELOUPE / GLOBAL / PAIN AND COMPLICATION MANAGEMENT / NOTABLE

Why it matters: This activates broader recruitment for a quadruple-masked Phase 3 test of whether lidocaine can reduce cumulative parenteral opioid use while also tracking pain, crisis resolution, complications, length of stay, quality of life and safety.

Evidence: ClinicalTrials.gov Phase 3 randomised trial registry change; high confidence.

Limitations: This is a registry-status change, not a result. The study is limited to adults admitted to intensive care, includes several medical exclusions and estimates primary and final completion on 3 August 2028. Site status can change again, and no results are posted.

Sources

• ClinicalTrials.gov: Intravenous lidocaine for opioid sparing in severe vaso-occlusive crisis: NCT07274254

The recruiting Phase 2 study moved estimated primary completion from 30 June 2026 to 30 June 2027 and final completion from 30 June 2027 to 30 December 2027.

Previous: Primary completion 30 June 2026; final completion 30 June 2027.

Current: Primary completion 30 June 2027; final completion 30 December 2027.

UNITED STATES / GLOBAL / CARDIAC COMPLICATIONS AND IRON OVERLOAD / NOTABLE

Why it matters: The one-year shift means evidence from the study is likely to arrive later than previously expected. Tracking the revised date prevents an already-passed estimate from being mistaken for completed research or imminent results.

Evidence: ClinicalTrials.gov registry milestone change; high confidence.

Limitations: This is an estimated-timeline change in a non-randomised, single-group study. It does not explain the delay, confirm when results will be published or establish that the screening and treatment strategy improves outcomes.

Sources

• ClinicalTrials.gov: Early detection and management of cardiac iron overload in sickle cell disease: NCT07023666

Tessera reported that one intravenous dose edited at least one HBB allele in an average of 85% of analysed long-term blood-forming stem cells in non-human primates. This is company-sponsored preclinical conference evidence, not an 85% clinical response or evidence from people with sickle cell disease.

UNITED STATES / GLOBAL / GENE EDITING AND DELIVERY / NOTABLE

Why it matters: This combines two ambitious changes to the current gene-editing process: correcting HBB rather than reactivating fetal haemoglobin, and performing the edit inside the body rather than collecting and modifying stem cells in a laboratory. If it translates safely to people, it could avoid stem-cell mobilisation, myeloablative conditioning and transplantation and make treatment easier to deliver globally.

Evidence: Company-sponsored non-human-primate data presented in a conference abstract; medium confidence.

Limitations: No person with sickle cell disease received this treatment. The 85% figure describes selected stem cells in non-human primates with at least one HBB allele edited, not an 85% cure rate, clinical response or confirmed correction of the sickle mutation in an animal with sickle cell disease. The results were produced and reported by Tessera, have no clinical comparator and do not establish durability, off-target safety, blood outcomes or prevention of vaso-occlusive events in humans. No named sickle-cell candidate or first-in-human date has been published.

Sources

• American Society of Gene and Cell Therapy: Therapeutically relevant levels of in vivo HBB gene correction in hematopoietic stem cells for sickle cell disease
• Tessera Therapeutics: New preclinical data advancing an in vivo sickle-cell programme

One person with HbSS had no reported vaso-occlusive episodes through 15.5 months after transformer base-edited autologous stem-cell therapy. It is a promising feasibility signal, not efficacy proof: only one person with sickle cell disease was reported, there was no comparator and the industry-sponsored Early Phase 1 trial is still recruiting.

CHINA / NIGERIA / GLOBAL / GENE AND CELL THERAPY / MAJOR

Why it matters: This is the first peer-reviewed clinical case reported for this transformer base-editing platform in sickle cell disease. It shows that the approach can edit and return a person's own blood stem cells and produce a strong fetal-haemoglobin response. It does not establish effectiveness across patients or justify calling the treatment a cure.

Evidence: Peer-reviewed descriptive report from three early trials; one participant had sickle cell disease; high confidence.

Limitations: Only one person with sickle cell disease was reported, with no comparator and 15.5 months of follow-up. The industry-sponsored Early Phase 1 trial is still recruiting, estimates five participants and has no registry results posted. The publisher's article describes busulfan-based myeloablative conditioning alongside cell collection, laboratory editing and reinfusion, so this is not chemotherapy-free. No off-target mutations were detected, but testing cannot prove that none occurred. Several authors are founders, advisers or employees of CorrectSequence Therapeutics.

Sources

• Cell Stem Cell / PubMed: Clinical base editing for beta-hemoglobinopathies across different genetic backgrounds
• ClinicalTrials.gov: Transformer base-edited autologous stem cells in severe sickle cell disease: NCT06565026
• ShanghaiTech University: Transformer base-editing therapy clinical report

The recruiting Early Phase 1 trial lists 31 December 2026 as its estimated primary completion and 30 June 2027 as its estimated final completion.

Previous: No CS-206 trial milestone recorded.

Current: Primary completion estimated 31 December 2026; final completion estimated 30 June 2027.

CHINA / NIGERIA / GLOBAL / GENE AND CELL THERAPY / MAJOR

Why it matters: This is the first peer-reviewed clinical case reported for this transformer base-editing platform in sickle cell disease. It shows that the approach can edit and return a person's own blood stem cells and produce a strong fetal-haemoglobin response. It does not establish effectiveness across patients or justify calling the treatment a cure.

Evidence: Peer-reviewed descriptive report from three early trials; one participant had sickle cell disease; high confidence.

Limitations: Only one person with sickle cell disease was reported, with no comparator and 15.5 months of follow-up. The industry-sponsored Early Phase 1 trial is still recruiting, estimates five participants and has no registry results posted. The publisher's article describes busulfan-based myeloablative conditioning alongside cell collection, laboratory editing and reinfusion, so this is not chemotherapy-free. No off-target mutations were detected, but testing cannot prove that none occurred. Several authors are founders, advisers or employees of CorrectSequence Therapeutics.

Sources

• ClinicalTrials.gov: Transformer base-edited autologous stem cells in severe sickle cell disease: NCT06565026

A single-centre review of 115 procedures in 50 people with HbSS found that automated exchange reduced mean HbS from 67.4% to 26.0%. The study has no comparator and cannot show that exchange caused the reported fall in crisis frequency.

INDIA / GLOBAL / TRANSFUSION AND SERVICE DELIVERY / NOTABLE

Why it matters: The study shows that a resource-intensive transfusion service can consistently reach its immediate HbS target at a high-burden centre in India. It adds practical evidence about delivering automated exchange outside the settings that dominate the published literature.

Evidence: Peer-reviewed single-centre retrospective observational study; high confidence.

Limitations: This was a retrospective study at one centre with no comparison group. Participants were selected for exchange, some had repeated procedures, and the fall in crisis frequency cannot be attributed to exchange alone. HbS reduction is an immediate laboratory endpoint, not proof of long-term benefit. The paper reports no external funding and no author conflicts.

Sources

• Indian Journal of Hematology and Blood Transfusion: Automated red blood cell exchange in sickle cell anaemia: a four-year retrospective study

A laboratory study found different gene-expression patterns in erythroid cells from hydroxyurea-treated and untreated patients. It generates mechanistic hypotheses, not a test that predicts response or evidence of a new treatment.

SWITZERLAND / GLOBAL / HYDROXYUREA AND DISCOVERY SCIENCE / NOTABLE

Why it matters: The work points to oxidative phosphorylation, proteasome, autophagy, immune and inflammatory pathways that may help explain disease biology or hydroxyurea response. These are hypotheses for further study, not new treatment targets ready for patients.

Evidence: Peer-reviewed laboratory transcriptomic study using patient-derived cells; high confidence.

Limitations: This is laboratory gene-expression research, not a clinical trial. The accessible abstract does not state the group sample sizes, and treatment groups may differ for reasons other than hydroxyurea. It does not show symptom improvement, establish causality or validate a response test. The authors declared no competing interests.

Sources

• Human Genomics: Transcriptomic signatures of hydroxyurea response in sickle cell disease

A hospital study found intestinal parasites in 86 of 100 children with sickle cell anaemia and 82 of 100 children without it. The difference was not statistically significant, pointing to a wider environmental health burden rather than sickle cell status alone.

SUDAN / GLOBAL / PAEDIATRICS AND INFECTION / NOTABLE

Why it matters: The striking result is the high burden in both groups. It points towards sanitation, water and wider environmental exposure as public-health concerns rather than evidence that sickle cell status itself caused more infection in this sample.

Evidence: Peer-reviewed single-hospital cross-sectional study; high confidence.

Limitations: The study was cross-sectional, used one hospital and analysed samples collected in 2022 to 2023. Microscopy can misclassify some species, and the design cannot establish infection incidence, clinical effects or causation. The study had no external funding and the authors declared no competing interests.

Sources

• BMC Pediatrics: Intestinal parasitic infections in Sudanese children with sickle cell anaemia

An integrative review of 11 articles links institutional racism and racial bias with mental-health burden and clinical management. The limited review method and small evidence set mean it does not quantify the size of these effects.

GLOBAL / CARE DISPARITIES / NOTABLE

Why it matters: It keeps discrimination and trust visible as clinical and service-quality issues, not separate social concerns. The review supports more equitable care and policy work, but it does not test a specific intervention.

Evidence: Peer-reviewed integrative review of 11 articles; high confidence.

Limitations: An integrative review is broader and less controlled than a systematic review. Only 11 articles were included, and the abstract does not provide effect sizes, detailed quality appraisal or enough information to quantify the impact of discrimination. The authors declared no competing interests.

Sources

• Hematology, Transfusion and Cell Therapy / PubMed: Racial discrimination and healthcare disparities in sickle cell disease

The MHRA accepted changes to Novo Nordisk's paediatric development plan for oral etavopivat in sickle cell disease. This is regulatory planning, not a marketing authorisation, efficacy result or NHS access decision.

UNITED KINGDOM / REGULATORY PIPELINE / NOTABLE

Why it matters: A paediatric investigation plan sets the studies and age-appropriate formulation work a developer must complete or defer as part of regulatory development. It shows that UK paediatric development remains active and now has a verified endpoint date.

Evidence: MHRA decision on a paediatric investigation plan modification; high confidence.

Limitations: The public decision records the plan and timing, not trial results or a regulatory benefit-risk conclusion. Studies may change, fail or take longer, and completing a plan does not guarantee approval or NHS funding. The applicant is Novo Nordisk Limited.

Sources

• MHRA: Modified paediatric investigation plan for etavopivat

The MHRA decision sets 31 July 2029 as the planned completion date for the modified paediatric investigation plan.

Previous: No verified UK paediatric-plan completion date recorded.

Current: Paediatric investigation plan completion due 31 July 2029.

UNITED KINGDOM / REGULATORY PIPELINE / NOTABLE

Why it matters: A paediatric investigation plan sets the studies and age-appropriate formulation work a developer must complete or defer as part of regulatory development. It shows that UK paediatric development remains active and now has a verified endpoint date.

Evidence: MHRA decision on a paediatric investigation plan modification; high confidence.

Limitations: The public decision records the plan and timing, not trial results or a regulatory benefit-risk conclusion. Studies may change, fail or take longer, and completing a plan does not guarantee approval or NHS funding. The applicant is Novo Nordisk Limited.

Sources

• MHRA: Modified paediatric investigation plan for etavopivat

A 91-patient single-centre cohort associated nonmyeloablative conditioning with less supportive care and no combined acute grade 2 to 4 or chronic graft-versus-host disease. Non-randomised groups and treatment-era differences prevent a causal comparison.

UNITED STATES / GLOBAL / STEM-CELL TRANSPLANTATION / NOTABLE

Why it matters: Conditioning toxicity is a major part of transplant burden. These results support further study of a lower-intensity approach that may reduce immediate toxicity and preserve ovarian reserve while still controlling sickle cell disease.

Evidence: Peer-reviewed single-centre mixed retrospective and prospective cohort; high confidence.

Limitations: The groups were not randomised, were treated over different eras and were very uneven in size. Myeloablative and reduced-intensity data were retrospective, while nonmyeloablative patients were enrolled in two trials. Selection and changing supportive care may explain part of the difference, and second transplants show a real engraftment trade-off.

Sources

• Transplantation and Cellular Therapy / PubMed: Conditioning intensity and outcomes in paediatric HLA-identical transplant

Claims data from 48,760 people found total opioid dispensing generally stabilised or increased from 2021 to 2023 without broad increases in dose, duration or frequency among recipients. Dispensing data cannot show pain control or medicine use.

UNITED STATES / GLOBAL / PAIN CARE AND ACCESS / NOTABLE

Why it matters: The pattern is more consistent with prescriptions reaching a wider share of people than with broadly more intense regimens among existing recipients. That matters after years of concern that general opioid restrictions can unintentionally reduce access to sickle-cell pain treatment.

Evidence: Peer-reviewed retrospective insurance-claims cohort; high confidence.

Limitations: Claims record outpatient dispensing, not whether medicines were taken, whether pain was adequately treated or why prescribing changed. The sample excludes uninsured people and other payers, its geographic mix changed over time, and the analysis cannot separate policy, pandemic and care-delivery effects. Several authors reported unrelated industry or other interests; study funding was mainly public and academic.

Sources

• JAMA Network Open: Opioid dispensing volume and per-patient intensity in sickle cell disease

Targeted sequencing in 40 people uncovered previously unreported variation around the beta-globin cluster and showed how a more complete reference genome changes variant calls. Clinical effects and treatment relevance remain unvalidated.

AFRICA / GLOBAL / GENOMICS AND RESEARCH EQUITY / NOTABLE

Why it matters: Reference genomes and databases underrepresent African variation even though sickle cell burden is highest in Africa. Better mapping of the beta-globin region may improve future research into disease severity, fetal haemoglobin and gene-based therapies.

Evidence: Peer-reviewed targeted long-read genomic study; high confidence.

Limitations: Only 40 people were sequenced. The reported variants and promoter insertion require replication and functional study, and no clinical association or treatment effect was established. This is discovery research, not a diagnostic test or evidence that current gene therapies work differently in a particular person.

Sources

• Human Genetics and Genomics Advances / PubMed: Long-read sequencing uncovers beta-globin variants in Africans with sickle cell disease

A review of 11 studies involving 1,630 children in low- and middle-income countries found that seven reported poorer academic performance among children with sickle cell disease. The evidence was too heterogeneous for meta-analysis.

LOW- AND MIDDLE-INCOME COUNTRIES / GLOBAL / PAEDIATRICS AND EDUCATION / NOTABLE

Why it matters: The review brings scattered education findings together and makes the effect of illness on school participation more visible. It supports further study of practical educational support alongside clinical care, particularly where children face both disease burden and limited resources.

Evidence: Peer-reviewed systematic review with narrative synthesis; high confidence.

Limitations: The studies used different academic measures, so the authors could not perform a meta-analysis. Most were cross-sectional, only English-language studies were included and the review cannot show that sickle cell disease alone caused the observed differences.

Sources

• Health Science Reports: Academic performance among children with sickle cell disease in low- and middle-income countries

A systematic review of 34 machine-learning studies found limited use of climate data and poor representation of high-burden regions. It identifies a research direction, not a validated clinical warning tool.

GLOBAL / DIGITAL HEALTH AND CLIMATE / NOTABLE

Why it matters: Combining personal health information with local weather and air-quality data could eventually support earlier warnings or service planning. The review identifies what would be needed next: longitudinal datasets, stronger climate integration, multicentre validation and more research in high-burden settings.

Evidence: Peer-reviewed systematic review; high confidence.

Limitations: This is a review of heterogeneous modelling studies, not a trial of a clinical warning system. Reported model performance cannot be assumed to transfer between populations, climates or health systems, and underrepresentation of sub-Saharan Africa limits relevance to much of the global disease burden.

Sources

• BMC Medical Informatics and Decision Making: Machine learning for predicting sickle-cell crisis and mortality at the climate-health nexus

An exploratory study used MRI to monitor marrow recovery after transplantation in a sickle-cell mouse model and two adults. The two-person human component shows feasibility only, not clinical validation.

UNITED STATES / GLOBAL / TRANSPLANTATION AND IMAGING / NOTABLE

Why it matters: A repeatable scan could potentially monitor marrow recovery without relying only on invasive biopsy. This study establishes a technically plausible signal to test in a larger human cohort, not a clinically ready biomarker.

Evidence: Peer-reviewed preclinical study with two-person human feasibility component; high confidence.

Limitations: Most of the evidence is from mice, and the human feasibility component included only two young adult men with no clinical comparator. It cannot establish diagnostic accuracy, thresholds, prediction, patient benefit or generalisability to other transplant and conditioning approaches.

Sources

• Journal of Magnetic Resonance Imaging: MRI proton density fat fraction as a biomarker of marrow recovery following organ-sparing total marrow irradiation
• PubMed: MRI marrow-recovery study record: PMID 42689386

A planned 120-person randomised study will compare a short educational video, an educational game and no intervention for self-care and self-efficacy. It is not yet recruiting and has inconsistent age and start-date fields.

IRAQ / GLOBAL / SELF-MANAGEMENT AND EDUCATION / NOTABLE

Why it matters: The study could help distinguish whether short digital education formats improve confidence and reported self-management in adolescents. Including an active format comparison may be more informative than evaluating one educational resource alone.

Evidence: New randomised supportive-care trial registry record; high confidence.

Limitations: This is a trial plan, not evidence of benefit. Recruitment has not started and the registry's estimated 1 September 2026 start predates its 3 September posting. The age field says 11 to 18 while the inclusion criteria say 12 to 18. Follow-up lasts one month and the outcomes are self-reported rather than clinical events.

Sources

• ClinicalTrials.gov: Educational video and game study for children with sickle cell disease: NCT07802210

A 246-person cross-sectional study found elevated urinary alpha-1 microglobulin in 48% of adults with stable sickle cell disease. It identifies a possible marker of proximal tubular injury, but does not show prediction or treatment benefit.

DEMOCRATIC REPUBLIC OF THE CONGO / GLOBAL / KIDNEY COMPLICATIONS / NOTABLE

Why it matters: Kidney damage in sickle cell disease is often discussed through albumin leakage and filtration. This study adds evidence that injury to the kidney's proximal tubules may also be common and that urinary alpha-1 microglobulin deserves prospective study as a marker.

Evidence: Peer-reviewed multicentre cross-sectional study; high confidence.

Limitations: The study was cross-sectional, so it cannot show whether the marker predicts kidney decline or whether hydroxyurea caused the lower odds observed. It was conducted in stable adults at one city network and did not test a screening or treatment pathway.

Sources

• Clinics: Proximal tubulopathy in adult sickle cell disease: association of alpha-1 microglobulin
• PubMed: Proximal tubulopathy study record: PMID 42685378

A 25-person US Phase 1 study will test a single dose of buccal buprenorphine while children and young adults transition from hydromorphone during an acute pain admission. Recruitment has not started.

UNITED STATES / GLOBAL / PAIN MANAGEMENT / NOTABLE

Why it matters: The study asks whether a partial opioid agonist can be introduced safely during an acute admission and reduce reliance on full opioid agonists. Its primary outcome is a 48-hour safety measure, with pain, opioid consumption and satisfaction as secondary outcomes.

Evidence: New Phase 1 clinical-trial registry record; high confidence.

Limitations: This is a small, single-centre, open-label Phase 1 plan, not evidence that buprenorphine is safer or more effective. Recruitment has not started, dates are estimates and the study is not designed to establish long-term benefit.

Sources

• ClinicalTrials.gov: Buprenorphine for pain in children with sickle cell disease: NCT07799571

Ain Shams University newly registered an ongoing Cairo cohort intended to describe clinical characteristics, complications, treatment and quality of life in 400 children and young adults.

EGYPT / GLOBAL / EPIDEMIOLOGY AND SERVICES / NOTABLE

Why it matters: A structured local registry can make disease patterns and care gaps more visible in Egypt and support later service planning or research. Its value will depend on completeness, consistent definitions and whether findings are published.

Evidence: New observational registry record; high confidence.

Limitations: This is registration of an ongoing single-institution, non-probability cohort, not a new treatment or result. The record supplies a broad registry objective and estimated dates but limited methodological detail.

Sources

• ClinicalTrials.gov: Ain Shams University sickle-cell institutional registry: NCT07800247

The single-group US study is now recorded as completed with 27 participants. No results have been posted, so the update does not establish diagnostic accuracy or clinical benefit.

Previous: Recruiting; 30 participants estimated; primary and final completion estimated 30 June 2026.

Current: Completed; 27 participants actual; primary and final completion 6 May 2026; no results posted.

UNITED STATES / GLOBAL / DIAGNOSTICS / NOTABLE

Why it matters: Lung ultrasound could offer a bedside, radiation-free complement to chest X-ray if later results establish reliable detection and useful clinical decisions.

Evidence: ClinicalTrials.gov registry status change; high confidence.

Limitations: Completion is not a result. No summary findings are posted, the study had no comparator and its listed primary outcomes focus on participation, retention, examination time and acceptability rather than diagnostic accuracy.

Sources

• ClinicalTrials.gov: Point-of-care ultrasound for acute chest syndrome: NCT06880679

The non-randomised US study is now recorded as completed with 18 participants. No results are posted, so this provides no evidence that the supplement helps people with sickle cell disease.

Previous: Recruiting; 15 participants estimated; primary completion estimated 30 December 2026 and final completion estimated 30 June 2027.

Current: Completed; 18 participants actual; primary completion 27 September 2022 and final completion 30 June 2025; no results posted.

UNITED STATES / GLOBAL / COMPLEMENTARY EVIDENCE / NOTABLE

Why it matters: The completed study may eventually add human evidence about a mitochondria-targeted antioxidant mechanism. At present, the update only confirms that data collection ended.

Evidence: ClinicalTrials.gov registry status change; high confidence.

Limitations: No results are posted. The study was very small, non-randomised, short-term and focused on laboratory markers rather than crises or patient outcomes. A supplement can still have adverse effects or interactions, so this record is not a basis for self-treatment.

Sources

• ClinicalTrials.gov: MitoQ platelet and oxidative-stress study: NCT04109820

The five-person stem-cell mobilisation pilot remains active, not recruiting, but its estimated primary and final completion moved by about eleven months.

Previous: Primary and final completion estimated 3 August 2026.

Current: Primary and final completion estimated 6 July 2027.

UNITED STATES / GLOBAL / GENE AND CELL THERAPY DELIVERY / NOTABLE

Why it matters: Plerixafor is used to move blood-forming stem cells into the bloodstream for collection. Safe, adequate collection is a practical part of autologous gene-therapy pathways, so a substantial follow-up delay matters even without a new efficacy result.

Evidence: ClinicalTrials.gov registry milestone change; high confidence.

Limitations: The registry does not explain the eleven-month delay. Only five participants were enrolled, no results are posted and the new dates remain estimates.

Sources

• ClinicalTrials.gov: Plerixafor stem-cell mobilisation pilot: NCT03664830

The 120-person randomised Phase 2 study remains labelled recruiting, but its estimated start moved from 1 April to 10 September 2026. This registry inconsistency needs confirmation from the study team.

Previous: Estimated start 1 April 2026.

Current: Estimated start 10 September 2026; recruitment status still listed as recruiting.

UNITED STATES / GLOBAL / PAIN MANAGEMENT / NOTABLE

Why it matters: The triple-masked design could produce more useful evidence about whether low-dose ketamine reduces opioid need during acute vaso-occlusive pain than uncontrolled treatment reports.

Evidence: ClinicalTrials.gov registry milestone change; high confidence.

Limitations: The registry still labels the study recruiting even though its revised start date is in the future. That inconsistency needs confirmation, and the update is a schedule change rather than a clinical result.

Sources

• ClinicalTrials.gov: Low-dose ketamine for acute sickle-cell pain: NCT07369024

A 147-participant Ghanaian study found that a proprietary non-albumin urine assay separated existing proteinuric from non-proteinuric groups, but it did not show earlier detection or improved patient outcomes.

GHANA / GLOBAL / DIAGNOSTICS / NOTABLE

Why it matters: The assay may be detecting a different mixture of urinary proteins from standard albumin testing. That creates a testable route toward finding kidney injury that albumin-only tests could miss, but this study did not establish that advantage.

Evidence: Peer-reviewed case-control proof-of-concept study; high confidence.

Limitations: This selected case-control study grouped participants using existing proteinuria status. It did not show earlier detection, predict outcomes or test clinical implementation. The proprietary reagents are patented, one author worked for the funding institute and two authors disclosed biotechnology or diagnostics consulting roles.

Sources

• Frontiers in Medicine: Novel urinary protein immunoassay in adults with sickle cell disease

The registry moved the study from suspended to active, not recruiting. It does not explain whether the earlier serious-adverse-event concern is resolved, and no results are posted.

Previous: Suspended; registry reason: enrolment held due to recent serious adverse events; 40 estimated participants.

Current: Active, not recruiting; 46 actual participants; primary completion 16 June 2026; final completion estimated August 2029.

UNITED STATES / GLOBAL / TRANSPLANTATION / NOTABLE

Why it matters: The study is again recorded as continuing follow-up after a long suspension. It tests lower-intensity matched-sibling and haploidentical transplantation in children and young adults, where reducing conditioning toxicity could widen curative options if safety and disease-free survival are acceptable.

Evidence: ClinicalTrials.gov registry status change; high confidence.

Limitations: A registry status change is not a safety finding or efficacy result. The new record removes the previous explanation but does not say whether the serious-adverse-event concern was resolved, whether treatment restarted or why the status changed. No results are posted.

Sources

• ClinicalTrials.gov: Reduced-intensity transplantation for severe sickle cell disease: NCT04362293

A US randomised mobile-health study is now recorded as completed with 239 adults. Completion is not evidence that the app worked, and no results are posted.

Previous: Recruiting; 185 participants estimated; completion estimated 30 June 2026.

Current: Completed; 239 participants actual; study completion 13 March 2026; no results posted.

UNITED STATES / GLOBAL / PAIN AND SELF-MANAGEMENT / NOTABLE

Why it matters: This is a relatively large completed behavioural trial focused on pain, stress and opioid use in adults with sickle cell disease. Its eventual results could show whether a supported mobile intervention adds benefit beyond symptom tracking alone.

Evidence: ClinicalTrials.gov registry status change; high confidence.

Limitations: Completion does not show benefit or safety. No summary results are posted and the registry provides no confirmed publication date, so effectiveness cannot yet be assessed.

Sources

• ClinicalTrials.gov: Stress and pain self-management mobile-health trial: NCT04484272

A 48-person US trial will compare an eight-week smartphone mindfulness programme with usual care for pain interference and sleep-related outcomes. Recruitment has not started.

UNITED STATES / GLOBAL / PAIN AND SLEEP / NOTABLE

Why it matters: It will test a low-burden supportive-care approach for two linked problems that can reinforce each other: pain and disrupted sleep. Randomisation should provide more useful evidence than an uncontrolled app evaluation.

Evidence: New ClinicalTrials.gov registry record; high confidence.

Limitations: This is a registry plan, not a result. The study is small, open-label, has not started recruitment and relies heavily on self-reported outcomes. Start and completion dates are estimates and may change.

Sources

• ClinicalTrials.gov: REMedy mindfulness trial for pain and sleep: NCT07797582

One new peer-reviewed narrative review was added. It questions routine macrolide use, but does not change UK guidance and is not randomised evidence.

UNITED STATES / GLOBAL / CLINICAL PRACTICE EVIDENCE / NOTABLE

Why it matters: If confirmed and adopted, a test-guided approach could reduce unnecessary macrolide exposure while preserving initial bacterial cover. It challenges pathways that routinely combine a cephalosporin with a macrolide.

Evidence: Peer-reviewed narrative review / expert opinion; high confidence.

Limitations: This is a narrative review and expert recommendation based largely on observational evidence, not a randomised antibiotic comparison or formal guideline. It needs prospective validation and depends on rapid, reliable respiratory testing and individual clinical context.

Sources

• Expert Review of Respiratory Medicine: Management of acute chest syndrome in children with sickle cell disease: impact of vaccination and respiratory panels
• PubMed: Paediatric acute chest syndrome review: PMID 42673552

The first 28 material records covering 15 November 2023 to 31 August 2026 were published as the starting state of the monitor.